# Initial Oxygen Use for Preterm Newborn Resuscitation: A Systematic Review With Meta-analysis

Michelle Welsford, BSc, MD, FRCPC,<sup>a,b</sup> Chika Nishiyama, RN, PhD,<sup>c</sup> Colleen Shortt, PhD,<sup>b</sup> Gary Weiner, MD,<sup>d</sup> Charles Christoph Roehr, MD, PhD,<sup>e,f</sup> Tetsuya Isayama, MD, MSc, PhD,<sup>g</sup> Jennifer Anne Dawson, RN, PhD,<sup>h</sup> Myra H. Wyckoff, MD,<sup>i</sup> Yacov Rabi, MD,<sup>j,k</sup> on behalf of the International Liaison Committee on Resuscitation Neonatal Life Support Task Force

**CONTEXT:** The International Liaison Committee on Resuscitation prioritized to review the initial fraction of inspired oxygen  $(F_{10_2})$  during the resuscitation of preterm newborns.

**OBJECTIVES:** This systematic review and meta-analysis provides the scientific summary of initial FIO<sub>2</sub> in preterm newborns (<35 weeks' gestation) who receive respiratory support at birth.

**DATA SOURCES**: Medline, Embase, Evidence-Based Medicine Reviews, and Cumulative Index to Nursing and Allied Health Literature were searched between January 1, 1980 and August 10, 2018.

**STUDY SELECTION**: Studies were selected by pairs of independent reviewers in 2 stages with a Cohen's κ of 0.8 and 1.0.

**DATA EXTRACTION:** Pairs of independent reviewers extracted data, appraised the risk of bias (RoB), and assessed Grading of Recommendations Assessment, Development and Evaluation certainty.

**RESULTS**: Ten randomized controlled studies and 4 cohort studies included 5697 patients. There are no statistically significant benefits of or harms from starting with lower compared with higher  $Fio_2$  in short-term mortality (n = 968; risk ratio = 0.83 [95% confidence interval 0.50 to 1.37]), long-term mortality, neurodevelopmental impairment, or other key preterm morbidities. A sensitivity analysis in which 1 study with a high RoB was excluded failed to reveal a reduction in mortality with initial low  $Fio_2$  (n = 681; risk ratio = 0.63 [95% confidence interval 0.38 to 1.03]).

LIMITATIONS: The Grading of Recommendations Assessment, Development and Evaluation certainty of evidence was very low for all outcomes due to RoB, inconsistency, and imprecision.

**CONCLUSIONS:** The ideal initial  $Fio_2$  for preterm newborns is still unknown, although the majority of newborns  $\leq 32$  weeks' gestation will require oxygen supplementation.



abstract

<sup>a</sup>Division of Emergency Medicine, McMaster University, Hamilton, Ontario, Canada; <sup>b</sup>Centre for Paramedic Education and Research, Hamilton Health Sciences, Hamilton, Ontario, Canada; <sup>c</sup>Department of Critical Care Nursing, Graduate School of Human Health Science, Kyoto University, Kyoto, Japan; <sup>d</sup>Department of Pediatrics and Communicable Diseases, University of Michigan and Charles Stewart Mott Children's Hospital, Ann Arbor, Michigan; <sup>e</sup>Medical Sciences Division, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; <sup>f</sup>Newborn Services, John Radcliffe Hospital, Oxford University Hospitals, National Health Service Foundation Trust, Oxford, United Kingdom; <sup>g</sup>Division of Neonatology, National Center for Child Health and Development, Tokyo, Japan; <sup>b</sup>Neonatal Services, The Royal Women's Hospital and The University of Melbourne, Melbourne, Australia; <sup>i</sup>Division of Neonatal–Perinatal Medicine, University

To cite: Welsford M, Nishiyama C, Shortt C, et al. Initial Oxygen Use for Preterm Newborn Resuscitation: A Systematic Review With Meta-analysis. *Pediatrics*. 2019;143(1):e20181828

The International Liaison Committee on Resuscitation (ILCOR) seeks to evaluate and promote the best available evidence on resuscitation by using a transparent and rigorous evaluation process conducted by a team of multidisciplinary experts culminating in a consensus on science with treatment recommendations (CoSTR).<sup>1</sup> In 2015, on the basis of the ILCOR's recommendations, guidelines from the American Heart Association and several other neonatal societies worldwide were updated to initiate the resuscitation of preterm newborns with a fraction of inspired oxygen (Fio<sub>2</sub>) between 0.21 and 0.30.<sup>2–4</sup>

These recommendations were based on evidence from randomized controlled trials (RCTs) that included relatively small numbers of preterm newborns. The ILCOR 2015 metaanalysis revealed no difference in outcomes when resuscitation was started with higher compared with lower Fio<sub>2</sub>. The final recommendation of lower F10, reflected a stated preference to avoid exposing preterm newborns to additional oxygen without evidence of benefit. After the ILCOR 2015 analysis was completed, the authors of the Targeted Oxygen in the Resuscitation of Preterm Infants and Their Developmental Outcomes (To2rpido) multinational RCT reported on a comparison of mortality of 292 preterm newborns who were resuscitated starting with either room air (Fio<sub>2</sub> 0.21) or pure oxygen (F10, 1.0).<sup>5</sup> The researchers in a nonprespecified subgroup analysis suggested that resuscitation with a starting F102 of 0.21 was associated with an increased risk of death in newborns <28 weeks' gestation. However, the study was nonblinded and was stopped prematurely because of recruitment difficulty and a lack of equipoise. Recently, the ILCOR has moved from a 5-yearly review cycle to a continuous evaluation process, and this allowed for an opportunity to

perform an updated analysis on this topic in which this newest study is incorporated.

Preterm newborns appear to be particularly at risk for the toxic effects of oxygen, perhaps related to reduced antioxidant defenses. The administration of high  $Fio_2$  leads to free radical formation and is toxic to the newborn lungs, eyes, brain, and other organs.<sup>6,7</sup> Given preterm newborns' incomplete lung, cardiac, and neurological development and immature oxidative defenses, the ideal  $Fio_2$  for initial resuscitation remains uncertain.<sup>8</sup>

The World Health Organization defines preterm newborns as infants who are born alive before 37 completed weeks' gestation (up to 36 weeks and 6 days). Extremely preterm is defined as <28 completed weeks' gestation, very preterm is 28 to <32 completed weeks' gestation, moderate preterm is 32 to <35 completed weeks' gestation, and late preterm is 35 to <37 completed weeks' gestation.9 Late-preterm newborns were grouped together with term newborns (37-42 weeks' gestation) in a separate systematic review and meta-analysis ( $\geq$ 35 weeks' gestation). Preterm newborns <35 weeks' gestation are included in this current meta-analysis.

This systematic review and metaanalysis is the core that serves as the consensus on science for the ILCOR CoSTR. It was completed in parallel and in collaboration with the ILCOR and is published separately from the ILCOR CoSTR, which will be published in the fall of 2019 and will be focused on the treatment recommendations. In cooperation with the ILCOR Neonatal Life Support (NLS) Task Force, in this metaanalysis, we investigate starting resuscitation with lower  $F_{10_2}$  ( $\leq 0.5$ ) compared with higher  $F_{10_2}$  (>0.5) on mortality and morbidity among preterm newborns (<35 weeks' gestation) who receive respiratory support at birth. The primary

outcome is short-term mortality (STM). Secondary outcomes include long-term mortality, neurologic outcomes, and important preterm morbidity.

#### **METHODS**

#### **Protocol**

This systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement for meta-analysis in health care interventions.<sup>10,11</sup> The protocol was registered in advance of article selection with the Prospective **Register of Systematic Reviews** (CRD42018084902, registered January 8, 2018; Supplemental Information). The protocol includes term and preterm newborns as predetermined subgroups, and these were separated into individual analyses after initial article selection. Studies were included in this systematic review if >75% of the newborns were <35 weeks' gestation.

#### **Outcomes**

The selection and importance rating of patient-oriented outcomes for preterm newborns were determined in advance through discussion and consensus with the ILCOR NLS Task Force.<sup>12</sup> The outcomes were centered on all-cause mortality at 2 time intervals, short-term (primary outcome, in the hospital, or up to 30 days postnatal) and long-term (1–3 years), as well as long-term neurodevelopmental impairment (NDI) (at 1-3 years). NDI is commonly defined as having at least 1 of the following and is categorized by severity: cerebral palsy, cognitive impairment, visual impairment, or hearing impairment. When available, we extracted data

for moderate-to-severe NDI at 1 to 3 years on the basis of the Gross Motor Function Classification System and the Bayley Scales of Infant Development, Third Edition.<sup>13,14</sup>

Additional preterm morbidities were captured: major intraventricular hemorrhage (IVH) (grade III or IV), according to the criteria of Papile et al<sup>15</sup>; severe retinopathy of prematurity (ROP) (stages III–V), defined in the International Classification of Retinopathy of Prematurity or on the basis of whether the infant received intravitreal or surgical treatment; necrotizing enterocolitis (NEC) (stage II or III), defined as modified Bell's stage II (pneumatosis) or III (surgical); and bronchopulmonary dysplasia (BPD) (moderate to severe), defined by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (2001) or on the basis of receiving supplemental oxygen at 36 weeks' corrected gestational age.<sup>16–19</sup> The important outcome of time to heart rate (HR) >100 beats per minute was preplanned, but when this was not available, HR (expressed as mean [SD] or median [interquartile range (IQR)]) at 1, 5, and 10 minutes was extracted. If this was not available, then a summary of the HR data provided was extracted.

#### **Search Strategy**

Ovid Medline, Embase, all Evidence-Based Medicine (EBM) Reviews (including the Cochrane Controlled Register of Trials and others), and EBSCOhost Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched for relevant neonatal literature between January 1, 1980, and December 11, 2017 (Supplemental Tables 13 and 14) without language restrictions. The search was updated from December 1, 2017, to August 10, 2018, before publication. The searches were limited to the last 4 decades because no pertinent studies were expected

before this. An iterative approach was used to ensure that key articles (identified by content experts and in previous systematic review articles) were found. Additionally, we searched the first 200 hits on Google Scholar, references of systematic reviews on the topic, references of the ILCOR 2015 CoSTR, and trial registries (the US National Library of Medicine [clinicaltrials.gov], the International Standard Randomized Controlled Trial Number registry [isrctn.com], and the European Union Clinical Trials Register [clinicaltrialsregister.eu]; last searched August 10, 2018).

#### Study Selection and Data Extraction

Covidence software was used for study selection in 2 steps (Covidence systematic review software; Veritas Health Innovation, Melbourne, Australia). Studies were included in this systematic review of FIO<sub>2</sub> management of preterm newborns if all subjects were born at <35 completed weeks' gestation. Pairs of independent reviewers screened titles and abstracts. In the event of a disagreement during the abstract screening, the full text was reviewed. Independent reviewers subsequently completed full-text review for eligibility in duplicate. A third reviewer was involved for disagreements at the full-text stage, and final decisions were determined by consensus. The first reason for exclusion was captured according to a predetermined, ordered list of exclusions. Interrater agreement for article selection was assessed by using Cohen's κ coefficient at the abstract and full-text stages.

#### RCTs, quasi-RCTs, and

nonrandomized (observational) studies were eligible if they included a comparison of low and high initial oxygen concentration for respiratory support at birth. Review articles, editorials, comments, case reports, and small case series ( $\leq 10$  patients) were excluded. Studies that focused on oxygen use beyond the initial stabilization in the delivery room or studies that were focused on oxygen saturation targeting and not initial oxygen concentration were also excluded. To avoid publication bias, the protocol was amended to include data from conference abstracts (not otherwise published) in a sensitivity analysis if the authors provided enough information to confirm the methods, key patient characteristics, and outcomes.

#### Data Collection, Risk of Bias, and Certainty of Evidence Assessment


For each study, pairs of authors independently extracted predetermined study characteristics and outcomes and then achieved consensus. Pairs of independent authors evaluated the risk of bias (RoB) in individual studies using the Cochrane Risk of Bias Tool for RCTs and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) Tool for observational studies.<sup>20,21</sup> Similarly, 2 authors assessed the certainty of evidence (confidence in the estimate of effect) for each outcome on the basis of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, including the calculation of the optimal information size to assess imprecision (GRADEpro Guideline Development Tool; McMaster University, Hamilton, Canada).<sup>22</sup> The RoB and GRADE assessments were then reviewed by ILCOR content experts, who are also authors, to achieve consistency and consensus.

#### **Data Analysis**

Covidence, GRADEpro, and Review Manager software 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) were used to abstract, summarize, and analyze the data, respectively. Meta-analyses were performed if  $\geq 2$  studies were available. Heterogeneity was measured by using the I<sup>2</sup> statistic.<sup>23</sup> Because multiple small studies (<250 patients) were anticipated, a random effects model was used for analysis. We report pooled unadjusted risk ratios (RRs) and corresponding 95% confidence intervals (CIs) using the Mantel-Haenszel (MH) method for dichotomous variables. Forest plots were used for the graphical representation of RRs. To assess for publication bias, we visually inspected funnel plots when >8 studies were available. The absolute risk difference and number needed to treat were calculated when the pooled estimate from RCTs revealed a statistically significant benefit when using the method recommended by the Cochrane Collaboration.<sup>10</sup>

Sensitivity analyses were completed when the inclusion of 1 or more studies was of a concern because of high RoB, incongruent allocation, a mixture of adjusted and nonadjusted analyses, or significant heterogeneity.

Prespecified subgroup analysis was planned if >2 studies were available with relevant outcome information related to gestational age groupings, initial Fio, groupings, or oxygen saturation targeting as a cointervention. Because extremely preterm newborns were categorized differently in the studies as being either up to 27 weeks and 6/7 days or up to 28 weeks and 6/7 days, we incorporated both and defined the following subgroups by gestational ages: ≤28, ≤32, or <35 weeks. In a post hoc exploratory analysis of the STM outcome for the  $\leq$ 28 weeks' gestation subgroup, the addition of a hypothetical large study to determine if it would change the statistical significance of the primary outcome was considered.



**FIGURE 1** 

PRISMA flow diagram of study selection.

#### RESULTS

# Literature Search and Study Selection

A total of 2366 records were identified with the search strategy, and after removing 967 duplicates, 1399 records were screened by title and abstract. Five additional studies (abstracts) were found via reference searches and added to full-text screening. A total of 59 full-text articles were assessed for eligibility, and 16 publications on preterm newborns were included.<sup>5,24–38</sup> Cohen's κ was 0.81 (excellent) at the abstract stage and 1.0 (full agreement) at the full-text stage. See Fig 1 for the PRISMA study selection diagram, including the reasons for article exclusion.

Of the additional studies considered via reference searches, 1 was a study of preterm newborns that was initially excluded but ultimately included: the study was published as a conference abstract only; however, the authors of a subsequent peer-review publication reported its methods and outcomes.<sup>32</sup> The senior author provided the abstract, conference poster, and additional data (including detailed methods, patient characteristics, and outcomes), and these were all consistent with the original abstract and the published data.<sup>32,34</sup>

One potentially eligible RCT was excluded from this review.<sup>39</sup> The researchers reported preliminary outcomes from the first 18 months of feasibility testing for a larger study that is included in this review.<sup>28</sup> To ensure duplicate data were not used, this was confirmed with the first author, and the preliminary report was excluded.

Lastly, a search of clinical trial registries (ClinicalTrials.gov, the International Standard RCT Number registry, and the European Union Clinical Trials Register) revealed no additional published studies, and 1 additional unpublished study, registered in 2012. The researchers in the Study of Room Air Versus 60% Oxygen for Resuscitation of Premature Infants aimed to randomly assign newborns  $\leq 28$ weeks' gestation to initial respiratory support with room air compared with Fio<sub>2</sub> 0.60. Recruitment began in 2013, and 1 of the primary investigators indicated that the study was stopped early because of funding, and no analyses have been published.<sup>40</sup>

#### **Study Characteristics**

Tables 1 and 2 include a summary of the characteristics of the included studies. Of the 16 included articles, 10 were RCTs, 2 were long-term follow-ups of included RCTs, and 4 were observational cohort studies.<sup>5,24–38</sup> Only 3 were fully randomized with fully blinded allocation and intervention.<sup>29,32,37</sup>

A total of 1007 preterm newborn patients were included in RCTs, ranging from 32 to 287 patients. Most of the studies were from Europe and North America; they were published between 1995 and 2017 with patient recruitment from 1991 to 2014. Three of the randomized trials were performed by a group of investigators using similar protocols.<sup>28,32,37</sup> Researchers in the 2 oldest RCTs did not monitor oxygen saturation during resuscitation and adjusted the inspired concentration on the basis of the newborn's HR.<sup>24,25</sup> One of the RCTs included 3 groups: a static concentration of F102 1.0 without titration and 2 with oxygen saturation targeting starting at either F10<sub>2</sub> 1.0 or room air. For the analyses, the latter 2 groups were used because they were closely matched comparisons and were similar to the remaining 7 other RCTs in which oxygen saturation targeting was used.29

Outcomes were extracted by using the definitions in the methods section with the following exceptions: Severe IVH (grades III–IV) was extracted as grades  $\geq$ II from 2 studies.<sup>32,37</sup> Severe ROP (stages III–V) was extracted as grades  $\geq$ 2 from 3 studies and as treated or blinded from 1 study.<sup>25,28,32,37</sup>

NEC (stages II–III) was extracted as all NEC in 1 study and as surgical (stage III) in 2 others.<sup>24–26</sup> The BPD definition has been updated over time, and thus, there were some minor differences.

In addition to the RCTs, a total of 4437 patients were included in 4 observational cohort studies ranging from 125 to 2326 patients.<sup>27,33,35,36</sup> The studies were from Australia, Canada (n = 2), and the United States and were published between 2009 and 2017 with patient recruitment from 2004 to 2012. Oxygen saturation targeting was included as a cointervention in all of these observational studies. Researchers in each of these studies described outcomes observed before and after the delivery room practice for oxygen administration was changed. Researchers in 2 studies compared initiating resuscitation with Fio<sub>2</sub> 1.0 (before) to resuscitation with F10<sub>2</sub> 0.21 (after).<sup>27,35</sup> Researchers in the other 2 studies compared initiating resuscitation with Fio, 1.0 (before) to 2 "after" cohorts: either Fio<sub>2</sub> 0.21 or an intermediate oxygen concentration of  $F_{10_2}$  0.22 to 0.99.<sup>33,36</sup> For these latter 2 studies, only the room air and Fio, 1.0 groups were used because the intermediate groups had a range of starting oxygen levels and could not be classified as low or high.

#### **Patient Characteristics**

In Tables 3 and 4, we outline the patient characteristics of included studies. The intervention and comparator groups were similar in key prognostic variables. The definition of prematurity for this review (<35 weeks' gestation) included a wide range of gestational ages with the potential for different oxygen requirements after birth. Despite the potential for significant heterogeneity in subject enrollment, the studies included subjects with similar postmenstrual ages and birth weights. Although most of the studies enrolled newborns  $\leq$  32 weeks' gestation, 7 RCTs included 467 extremely preterm newborns ( $\leq$  28 weeks' gestation), and researchers either reported separate data for this subgroup or they provided additional data for subgroup analyses.<sup>5,26,28,29,31,32,37</sup>

### RoB

The RoB assessment for each study is summarized in Tables 5 and 6. Researchers in only 3 RCTs provided evidence that they were able to fully blind personnel to the Fio<sub>2</sub> used.<sup>29,32,37</sup> Many of the studies were determined to have an unclear RoB due to uncertainty regarding the blinding of outcome assessors and bias due to potential deviations from intended interventions.

One study (2 publications) was determined to have a high RoB due to a lack of blinding of personnel, a low recruitment rate, and the early termination of the study due to poor recruitment.<sup>5,38</sup> Researchers in the To2rpido trial intended to include ~2000 newborns <32 weeks' gestation and screened >6000 newborns, but they stopped after 6.5 years, having recruited only 292 newborns, partly because of a lack of clinical equipoise of using  $Fio_2$  1.0 for initial resuscitation.

## **Outcome Analysis**

Results of the meta-analysis are summarized in Tables 7 through 11, reviewed below, and key analyses are shown in the Figs 2 and 3 forest plots. Additional material is located in the forest plots of Supplemental Figs 4 and 5.

#### All Preterm Newborns <35 Weeks' Gestation

For the primary outcome, researchers in 10 RCTs involving 968 preterm newborns reported on STM (at hospital discharge or 30 days).<sup>5,24–26,28–32,37</sup> The pooled estimate revealed no statistically significant STM difference in starting

| Years of<br>Recruitment<br>Recruitment<br>Bacining et al24<br>Wang et al28YA<br>1991–1992<br>N/A<br>N/AUundstrøm1991–1992<br>al24<br>N/AWang et al24<br>Wang et al282005–2007Vento et al282005–2008Rabi et al292005–2007Rabi et al292005–2007Badiee <sup>50</sup> 2009–2010 | Country of<br>Recruitment<br>Denmark<br>United<br>Kingdom<br>United States |                               |                      |                   |     | ABC, WN        | uxygen | 0xygen Levels, <i>n</i> | Level                            |   | Sub | Subgroup, wk | ۲×  |     |     |     |       |
|---|--|-------------------------------|----------------------|-------------------|-----|----------------|--------|-------------------------|----------------------------------|---|-----|--------------|-----|-----|-----|-----|-------|
|   | Denmark<br>United<br>Kingdom<br>United States                              | Multi- or<br>Single<br>Center | Study Design         | Blinded<br>to Gas |     |                | Low    | High                    | Definition,<br>%                 |   | ≤28 | ≤32          | <35 | STM | LTM | IQN | Other |
|   | United<br>Kingdom<br>United States   | Single                        | RCT<br>(convenience) | No                | 70  | <33            | 34     | 36                      | Low 21;<br>high 80               | N/A                                       |     |              | Yes | Yes |     |     | Yes   |
|   | United States  | Single                        | RCT                  | No                | 52  | <31            | 26     | 26                      | Low 50;<br>hiéh 100              | N/A                                       |     | Yes          | Yes | Yes |     |     | Yes   |
|   |  | Multi                         | RCT                  | No                | 41  | <32            | 18     | 23                      | Low 21;<br>high 100              | 80%—85%<br>at 5 min,<br>maintain<br>after | Yes | Yes          | Yes | Yes |     |     | Yes   |
|   | Spain  | Single                        | RCT                  | Partial           | 78  | ≤28            | 37     | 41                      | Low 30;<br>high 90               | 7 min<br>Titrated to<br>attain<br>oxygen  | Yes | Yes          | Yes | Yes |     |     | Yes   |
|   | Canada   | Single                        | RCT                  | Yes               | 106 | ≤32            | 34     | 34                      | Low 21;<br>hidh 100              | saturation<br>85%–92%                     | Yes | Yes          | Yes | Yes |     |     | Yes   |
|   | Iran   | Single                        | RCT                  | N                 | 32  | <35<br>(29–34) | 16     | 16                      | nigin 100<br>Low 30;<br>high 100 | Titrated to HR<br>>100 beats<br>per min   |     |              | Yes | Yes |     |     |       |
|   |  |                               |                      |                   |     |                |        |                         |                                  | saturation<br>>85%                        |     |              |     |     |     |     |       |
| Kapadia 2010–2011<br>et al <sup>š1</sup>  | United States  | Single                        | RCT                  | No                | 88  | <35            | 44     | 44                      | Low 21;<br>high 100              | 88%–94%                                   | Yes | Yes          | Yes | Yes |     |     | Yes   |
| Aguar et al <sup>32</sup> 2008–2012   | Spain  | Single                        | RCT                  | Yes               | 60  | ≤28            | 34     | 26                      | Low 30;<br>high 60               | 88%–94%<br>at 10 min<br>after birth       | Yes | Yes          | Yes | Yes |     |     | Yes   |
| Rook et al <sup>37</sup> 2008–2012  | Netherlands  | Single                        | RCT                  | Yes               | 193 | <32            | 66     | 94                      | Low 30;<br>high 65               | 88%–94%<br>at 10 min<br>after birth       | Yes | Yes          | Yes | Yes |     |     | Yes   |
| Boronat 2008–2012<br>et al <sup>34</sup>  | Spain,<br>Netherlands  | Multi                         | RCT                  | Yes               | 253 | <32            | 133    | 120                     | Low 30;<br>high 60<br>or 65      | 88%–94%<br>at 10 min<br>after birth       |     | Yes          | Yes |     | Yes | Yes |       |
| 0ei et al <sup>5</sup> 2008–2014<br>(To2rpido)  | Australia,<br>Malaysia,<br>Qatar   | Multi                         | RCT                  | No                | 287 | <32            | 144    | 143                     | Low 21;<br>high 100              | 80%-95% at<br>5-10 min                    | Yes | Yes          | Yes | Yes |     |     | Yes   |
| Thamrin 2008–2014<br>et al <sup>38</sup><br>(To2rpido)  | Australia,<br>Malaysia,<br>Qatar   | Multi                         | RCT                  | No                | 238 | <32            | 117    | 121                     | Low 21;<br>high 100              | 80%–95% at<br>5–10 min                    | Yes |              | I   |     | Yes | Yes |       |

| TABLE 2 Stuc                     | ly Characterist         | ics in Preterm (   | (<35 Weeks) F                 | TABLE 2 Study Characteristics in Preterm (<35 Weeks) Retrospective Observational Cohort Studies | servational ( | Cohort Stud       | ies   |                                     |                         |                     |                              |            |                         |     |         |         |     |       |
|----------------------------------|-------------------------|--|-------------------------------|---|---------------|-------------------|---|-------------------------------------|-------------------------|---------------------|------------------------------|------------|-------------------------|-----|---------|---------|-----|-------|
| Study                            |                         | Stud   | Study Characteristics         | tics  |               | Total<br>Patients | Gestational Patients by Oxygen<br>Age, wk Levels, n | Patients by 0xy<br>Levels, <i>n</i> | y Oxygen<br>s, <i>n</i> | Oxygen<br>Level     | 0 <sub>2</sub> Sat<br>Target | P1<br>Subg | Preterm<br>Subgroup, wk | ×   |         | Outcome | ome |       |
|                                  | Years of<br>Recruitment | Years of Country of<br>Recruitment Recruitment                   | Multi- or<br>Single<br>Center | Design  | Blinded       |                   |   | Low                                 | High                    | Definition,<br>%    |                              | ≤28 ≤32    | ≤32                     | <35 | <35 STM | LTM NDI |     | Other |
| Dawson et<br>al <sup>27</sup>    | 2006–2007               | Australia  | Single                        | Prospective<br>before and<br>after  | No            | 125               | <30   | 105                                 | 20                      | Low 21; high<br>100 | %06                          |            | Yes                     | Yes | Yes     | I       |     |       |
| Rabi et al <sup>33</sup>         | 2004–2009               | Canada   | Multi                         | Retrospective<br>cohort   | No            | 2326              | <28   | 1244                                | 1082                    | Low 21; high<br>100 | Various                      | Yes        | Yes                     | Yes | Yes     |         |     | Yes   |
| Soraisham<br>et al <sup>36</sup> | 2010–2011               | Canada   | Multi                         | Retrospective<br>cohort   | No            | 1825              | ≤28   | 445                                 | 581                     | Low 21; high<br>100 | Various                      | Yes        | Yes                     | Yes | Yes     | Yes     | Yes | Yes   |
| Kapadia et<br>al <sup>35</sup>   | 2009–2012               | United<br>States   | Single                        | Retrospective<br>before and<br>after  | No            | 161               | ≤28   | 89                                  | 110                     | Low 21; high<br>100 | 85%94%                       | Yes        | Yes                     | Yes | Yes     | Yes     | Yes | Yes   |
| LTM, long-term r                 | nortality; N/A, not     | LTM, long-term mortality; N/A, not available; —, not applicable. | ipplicable.                   |   |               |                   |   |                                     |                         |                     |                              |            |                         |     |         |         |     |       |

respiratory support with lower compared with higher oxygen concentration (RR = 0.83 [95% CI 0.50 to 1.37];  $I^2 = 18\%$ ). The forest plot is presented in Fig 2A, and the RRs are reported in Table 7. The funnel plot (Supplemental Fig 4) revealed reasonable study distribution, although unpublished small studies with negative or neutral results are possible. Clinical heterogeneity was low to moderate, and statistical heterogeneity was low ( $I^2 = 18\%$ ).

Sensitivity analysis was conducted for STM to determine the effect of including or excluding the To2rpido study given its high RoB.<sup>5</sup> The point estimate for STM for this study is contradictory to the majority of studies (Fig 2A). Excluding the To2rpido study would change the point estimate and CIs to RR 0.63  $(95\% \text{ CI } 0.38 \text{ to } 1.03; \text{ I}^2 = 0\%).$ However, because the RoB was high but not critical, we included this study in all other outcomes and subgroups. To further explore the reasons for heterogeneity, a sensitivity analysis was conducted for STM to compare the blinded and unblinded studies (Fig 2B). The point estimate for STM for the blinded studies is RR 0.51 (95% CI 0.25 to 1.02;  $I^2 = 0\%$ ).

Long-term mortality was reported in 3 RCTs (2 were combined in 1 publication) at 2 years' follow-up involving 491 preterm newborns. Pooled estimates revealed no statistically significant difference in starting with lower compared with higher  $F_{10_2}$  (RR = 1.05 [95% CI 0.32 to 3.39]; I<sup>2</sup> = 79%).<sup>5,34</sup> This outcome revealed high heterogeneity, as evidenced by a visual inspection of the forest plot and statistical heterogeneity  $(I^2 = 79\%; Supplemental Fig 5A).$ Because RCT data for long-term mortality at 2 years were found in only 2 publications of 3 studies and had high heterogeneity, data from observational cohort studies were

| <b>TABLE 3</b> Patient Characteristics | s in Preterm | RCTs and | Quasi-RCTs |
|--|--------------|----------|------------|
|--|--------------|----------|------------|

| Study                                     | Oxygen<br>Level | Gestational<br>Age, wk  | Male<br>Sex, % | Birth Wt, g                   | Antenatal Steroid<br>Administration, % | Cesarean<br>Delivery, % | Intubation<br>and<br>Mechanical<br>Ventilation, % | Chest<br>Compressions, % |
|---|-----------------|-------------------------|----------------|-------------------------------|--|-------------------------|---|--------------------------|
| Lundstrøm et al <sup>24</sup>             |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 29 (25–32) <sup>a</sup> | 71             | 1043 (610–2590) <sup>a</sup>  | 88                                     | 68                      | 0   | N/A                      |
|   | High            | 29 (24–32) <sup>a</sup> | 61             | 1113 (550–1870) <sup>a</sup>  | 86                                     | 81                      | 0   | N/A                      |
| Harling et al <sup>25</sup>               |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 27 (23–31) <sup>a</sup> | 42             | 1010 (518–1528) <sup>a</sup>  | 100                                    | 39                      | N/A   | N/A                      |
|   | High            | 28 (24–30) <sup>a</sup> | 50             | 973 (560-1562) <sup>a</sup>   | 100                                    | 50                      | N/A   | N/A                      |
| Wang et al <sup>26</sup>                  |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 28.1 (2.2) <sup>b</sup> | 39             | 1066 (368) <sup>b</sup>       | 62                                     | 50                      | 55  | 0                        |
|   | High            | 27.6 (2.1) <sup>b</sup> | 39             | 1013 (444) <sup>b</sup>       | 74                                     | 70                      | 43  | 13                       |
| Vento et al <sup>28</sup>                 |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 26.0 (1.5) <sup>b</sup> | 38             | 854.7 (170.1) <sup>b</sup>    | 97                                     | 51                      | 57  | N/A                      |
|   | High            | 26.3 (1.3) <sup>b</sup> | 44             | 901.7 (195.4) <sup>b</sup>    | 93                                     | 59                      | 61  | N/A                      |
| Rabi et al <sup>29</sup>                  |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 29 (28–30) <sup>a</sup> | 53             | 1242 (1092–1391) <sup>a</sup> | 85                                     | N/A                     | 29  | N/A                      |
|   | High            | 29 (28–30) <sup>a</sup> | 35             | 1231 (1091–1371) <sup>a</sup> | 85                                     | N/A                     | 26  | N/A                      |
| Armanian and<br>Badiee <sup>30</sup>      |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | Mean 32                 | N/A            | Mean 1700                     | N/A                                    | N/A                     | N/A   | N/A                      |
|   | High            | Mean 30.8               | N/A            | Mean 1600                     | N/A                                    | N/A                     | N/A   | N/A                      |
| Kapadia et al <sup>31</sup>               |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 30 (24–34) <sup>a</sup> | 48             | 1678 (634) <sup>b</sup>       | 55                                     | 63                      | 20  | 0                        |
|   | High            | 30 (24–34) <sup>a</sup> | 55             | 1463 (6606) <sup>b</sup>      | 48                                     | 73                      | 39  | 0                        |
| Aguar et al <sup>32</sup>                 |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 27.1 (1.6) <sup>b</sup> | 74             | 1013 (306) <sup>b</sup>       | 100                                    | 65                      | N/A   | N/A                      |
|   | High            | 26.7 (1.5) <sup>b</sup> | 60             | 925 (174) <sup>b</sup>        | 100                                    | 60                      | N/A   | N/A                      |
| Rook et al <sup>37</sup>                  |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 29 (27–30) <sup>a</sup> | 44             | 1013 (820–1280) <sup>a</sup>  | 100                                    | 70                      | 31  | N/A                      |
| 74  | High            | 29 (26–31) <sup>a</sup> | 46             | 1123 (790–1368) <sup>a</sup>  | 100                                    | 65                      | 30  | N/A                      |
| Boronat et al <sup>34</sup>               |                 |                         |                | /                             |  |                         |   |                          |
|   | Low             | 28 (24–32) <sup>a</sup> | 48             | 944 (720–1280) <sup>a</sup>   | 100                                    | 68                      | N/A   | N/A                      |
| - · · · · F                               | High            | 27 (23–31) <sup>a</sup> | 52             | 1040 (755–1368) <sup>a</sup>  | 100                                    | 63                      | N/A   | N/A                      |
| 0ei et al <sup>5</sup><br>(To2rpido)      |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 28 (2) <sup>b</sup>     | 55             | 1147 (363) <sup>b</sup>       | 97                                     | 66                      | 30  | 1                        |
|   | High            | 28 (2) <sup>b</sup>     | 50             | 1136 (321) <sup>b</sup>       | 97                                     | 76                      | 29  | 0                        |
| Thamrin et al <sup>38</sup><br>(To2rpido) |                 |                         |                |                               |  |                         |   |                          |
|   | Low             | 28 (2) <sup>b</sup>     | 55             | 1147 (363) <sup>b</sup>       | 97                                     | 66                      | 30  | 1                        |
|   | High            | 28 (2) <sup>b</sup>     | 50             | 1136 (321) <sup>b</sup>       | 97                                     | 76                      | 29  | 0                        |

N/A, not available (not collected in original study).

<sup>a</sup> Reported as median (IQR).

<sup>b</sup> Reported as mean (SD).

also considered. Two observational cohort studies involving 1225 preterm newborns receiving respiratory support at birth revealed a statistically significant benefit of starting with lower compared with higher  $Fio_2$  (RR = 0.77 [95% CI 0.59 to 0.99]; I<sup>2</sup> = 6%; Supplemental Fig 5B).

Long-term NDI (1–3 years) was reported in 3 RCTs (2 publications) involving 389 preterm newborns receiving respiratory support at birth, and these revealed no statistically significant difference in starting with lower compared with higher  $F_{10_2}$  (RR = 1.14 [95% CI 0.78 to 1.67]; I<sup>2</sup> = 0%; Supplemental Fig 5C).<sup>34</sup> Because there were limited RCT data, 2 observational cohort studies involving 930 preterm newborns receiving respiratory support at birth were also considered. They revealed no statistically significant difference in starting with lower compared with higher  $F_{IO_2}$  (RR = 0.89 [95% CI 0.66 to 1.20];  $I^2 = 59\%$ ; Supplemental Fig 5D).

Time to HR >100 beats per minute was defined as a secondary outcome, but there was limited direct evidence available. Researchers in only 4 RCTs and 1 observational cohort study reported HR response in the first 10 minutes, and because it was reported differently in those studies, it precluded meta-analysis. One study revealed a significantly lower HR in the lower FI0<sub>2</sub> group until 3 to

| <b>TABLE 4</b> Patient Characteristics in Preterm F | Retrospective Observational Cohort Studies |
|---|--|
|---|--|

| Study                            | Oxygen<br>Level | Gestational Age, wk,<br>Mean (SD) | Male<br>Sex, % | Birth Wt, g,<br>Mean (SD) | Antenatal Steroid<br>Administration, % | Cesarean<br>Delivery, % | Intubation and<br>Mechanical<br>Ventilation, % | Chest<br>Compressions, % |
|----------------------------------|-----------------|-----------------------------------|----------------|---------------------------|--|-------------------------|--|--------------------------|
| Dawson et al <sup>27</sup>       |                 |                                   |                |                           |  |                         | · · · · · ·                                    |                          |
| barroon of ar                    | Low             | 27 (1.6)                          | 64             | 930 (293)                 | 82                                     | N/A                     | 0  | 0                        |
|                                  | High            | 27 (1.6)                          | 65             | 915 (300)                 | 90                                     | N/A                     | 40   | 0                        |
| Rabi et al <sup>33</sup>         | 0               |                                   |                |                           |  |                         |  |                          |
|                                  | Low             | 26 (25–27) <sup>a</sup>           | 54             | 884 (284)                 | 85                                     | 58                      | 36   | N/A                      |
|                                  | High            | 26 (25–27) <sup>a</sup>           | 51             | 843 (196)                 | 87                                     | 55                      | 38   | N/A                      |
| Soraisham et<br>al <sup>36</sup> |                 |                                   |                |                           |  |                         |  |                          |
|                                  | Low             | 26.3 (1.4)                        | 51             | 917 (216)                 | 93                                     | 61                      | N/A  | N/A                      |
|                                  | High            | 25.8 (1.5)                        | 53             | 851 (217)                 | 92                                     | 57                      | N/A  | N/A                      |
| Kapadia et al <sup>35</sup>      |                 |                                   |                |                           |  |                         |  |                          |
|                                  | Low             | 26 (1)                            | 48             | 983 (224)                 | 51                                     | 66                      | 70   | 2                        |
|                                  | High            | 26 (1)                            | 53             | 939 (255)                 | 54                                     | 67                      | 58   | 1                        |

N/A, not available (not collected in original study).

<sup>a</sup> Reported as median (IQR).

# **TABLE 5** RoB According to Cochrane RCT Criteria

| Study                             | Sequence<br>Generation | Allocation<br>Concealment | Blinding of<br>Participants<br>and<br>Personnel | Blinding of<br>Outcome<br>Assessors | Incomplete<br>Outcome Data | Selective<br>Outcome<br>Reporting | Other Sources<br>of Bias | Overall Bias |
|-----------------------------------|------------------------|---------------------------|---|-------------------------------------|----------------------------|-----------------------------------|--------------------------|--------------|
| Lundstrøm et al <sup>24</sup>     | Unclear                | Unclear                   | High  | Unclear                             | Low                        | Low                               | Unclear                  | Unclear      |
| Harling et al <sup>25</sup>       | Low                    | Unclear                   | Unclear   | Unclear                             | Low                        | Low                               | Low                      | Unclear      |
| Wang et al <sup>26</sup>          | Low                    | Low                       | High  | Unclear                             | Low                        | Unclear                           | Low                      | Unclear      |
| Vento et al <sup>28</sup>         | Low                    | Low                       | Unclear   | Low                                 | Low                        | Low                               | Low                      | Low          |
| Rabi et al <sup>29</sup>          | Low                    | Low                       | Low   | Low                                 | Low                        | Low                               | Unclear                  | Low          |
| Armanian and Badiee <sup>30</sup> | Unclear                | Unclear                   | Unclear   | Unclear                             | Low                        | Unclear                           | High                     | Unclear      |
| Kapadia et al <sup>31</sup>       | Low                    | Low                       | High  | Unclear                             | Low                        | Low                               | Unclear                  | Unclear      |
| Aguar et al <sup>32</sup>         | Low                    | Low                       | Low   | Low                                 | Low                        | Unclear                           | High                     | Unclear      |
| Rook et al <sup>37</sup>          | Low                    | Low                       | Low   | Unclear                             | Low                        | Low                               | Unclear                  | Unclear      |
| Boronat et al <sup>34</sup>       | Low                    | Low                       | Low   | Low                                 | Unclear                    | Low                               | Unclear                  | Unclear      |
| 0ei et al <sup>5</sup> (To2rpido) | Low                    | Low                       | High  | Low                                 | Low                        | Low                               | High                     | High         |
| Thamrin et al <sup>38</sup>       | Low                    | Low                       | High  | Low                                 | Unclear                    | Low                               | High                     | High         |

#### TABLE 6 RoB According to ROBINS-I Observational Cohort

| Study                            | Bias Due to<br>Confounding | Bias in<br>Selection of<br>Participants | Bias in<br>Classification<br>of<br>Interventions | Bias Due to<br>Deviations<br>From Intended<br>Interventions | Bias Due to<br>Missing Data | Bias in<br>Measurement<br>of Outcomes | Bias in<br>Selection of<br>the Reported<br>Result | Overall Bias |
|----------------------------------|----------------------------|---|--|---|-----------------------------|---------------------------------------|---|--------------|
| Dawson et al <sup>27</sup>       | Unclear                    | High                                    | Low  | Unclear   | Low                         | Low                                   | Low   | Unclear      |
| Rabi et al <sup>33</sup>         | Unclear                    | Low                                     | High   | High  | Low                         | Low                                   | Low   | Unclear      |
| Soraisham et<br>al <sup>36</sup> | Unclear                    | Low                                     | Unclear  | High  | Low                         | Low                                   | Low   | Unclear      |
| Kapadia et al <sup>35</sup>      | Unclear                    | Low                                     | Low  | High  | Low                         | Low                                   | Low   | Unclear      |

#### **TABLE 7** Summary of Results for All Preterm Newborns <35 Weeks' Gestation</th>

| Outcome                     | Study Design | No. Studies | No. Participants | Effect Estimate, RR (95% CI) | I <sup>2</sup> , % | GRADE Confidence |
|-----------------------------|--------------|-------------|------------------|------------------------------|--------------------|------------------|
| STM                         | RCT          | 10          | 968              | 0.83 (0.50 to 1.37)          | 18                 | Very low         |
| Long-term mortality         | RCT          | 3           | 491              | 1.05 (0.32 to 3.39)          | 79                 | Very low         |
| NDI long-term               | RCT          | 3           | 389              | 1.14 (0.78 to 1.67)          | 0                  | Very low         |
| ROP                         | RCT          | 7           | 806              | 0.73 (0.42 to 1.27)          | 0                  | Very low         |
| NEC                         | RCT          | 8           | 847              | 1.34 (0.63 to 2.84)          | 0                  | Very low         |
| BPD                         | RCT          | 8           | 843              | 1.00 (0.71 to 1.40)          | 47                 | Very low         |
| Major IVH (grade III or IV) | RCT          | 7           | 795              | 0.96 (0.61 to 1.51)          | 0                  | Very low         |

|   | Preterm, Low   | 2  | eterm, High  | 4  |   | RR  | v   |             |                         | R                            |   |
|---|--|--|--|--|---|---|---|-------------|-------------------------|------------------------------|---|
| Study or Subgroup   | Events   | Total  | Events   | Total V  | Veight  | M-H, RE, 95% CI   | Year  |             | M-H, RE                 | i, 95% Cl                    |   |
| 1.1 Mortality short te  |  |  |  |  |   |   |   |             |                         |                              |   |
| undstrom 1995   | 2  | 34   | 6  | 35   | 9.2%  | 0.34 (0.07 to 1.58)   | 1995  |             | -                       | <u> </u>                     |   |
| arling 2005   | 4  | 26   | 5  | 26   | 13.7%   | 0.80 (0.24 to 2.65)   | 2005  |             |                         |                              |   |
| /ang 2008   | 1  | 18   | 1  | 23   | 3.3%  | 1.28 (0.09 to 19.06)  | 2008  |             |                         | •                            |   |
| ento 2009   | 4  | 37   | 3  | 41   | 10.3%   | 1.48 (0.35 to 6.17)   | 2009  |             | 1.0                     | •                            |   |
| abi 2011  | 1  | 34   | 2  | 34   | 4.2%  | 0.50 (0.05 to 5.26)   | 2011  | •           | · · ·                   |                              |   |
| rmanian 2012  | 0  | 16   | 0  | 16   |   | Not estimable   | 2012  |             |                         |                              |   |
| apadia 2013   | 2  | 44   | 3  | 44   | 7.3%  | 0.67 (0.12 to 3.80)   | 2013  | · · · · · · |                         |                              |   |
| guar 2013   | 4  | 34   | 7  | 26   | 15.2%   | 0.44 (0.14 to 1.34)   | 2014  |             |                         | <u> </u>                     |   |
| ook 2014  | 6  | 99   | 10   |  | 18.7%   | 0.57 (0.22 to 1.51)   | 2014  |             |                         | <u> </u>                     |   |
| ubtotal (95% CI)  |  | 342  |  |  | 81.9%   | 0.63 (0.38 to 1.03)   |   |             |                         | -                            |   |
| otal events   | 24   |  | 37   |  |   | . ,   |   |             | -                       |                              |   |
| leterogeneity. $\tau^2 = 0.00$ ;<br>est for overall effect: z =   | ; χ <sup>2</sup> = 2.88, df =  |  |  |  |   |   |   |             |                         |                              |   |
| .1.2 Mortality short-te   | erm, RCT, high   | RoB  |  |  |   |   |   |             |                         |                              |   |
| ei 2017   | 14   | 144  | 5  | 143  | 18.1%   | 2.78 (1.03 to 7.52)   | 2017  |             |                         |                              |   |
| ubtotal (95% CI)  |  | 144  | 0  |  | 18.1%   | 2.78 (1.03 to 7.52)   |   |             |                         |                              |   |
| otal events   | 14   |  | 5  |  |   | ( · · · · · · · · · · · · · · · · · · ·   |   |             |                         |                              |   |
| leterogeneity. Not appli<br>est for overall effect: z =   | cable  |  | 0  |  |   |   |   |             |                         |                              |   |
|   | <u> </u>   | 486  |  | 192 4  | 00.0%   | 0 92 (0 50 to 1 27)   |   |             |                         |                              |   |
| otal (95% CI)   | ~~   | 400  | 40   | 482 1  | 00.0%   | 0.83 (0.50 to 1.37)   |   |             |                         |                              |   |
| otal events   | 38   |  | 42   |  |   |   |   |             |                         |                              |   |
| leterogeneity. $\tau^2 = 0.11$ ;  |  | 8 (P = .28)  | : 1~ = 18%   |  |   |   |   | 0.05        |                         | 1 5                          |   |
|   |  |  | ,  |  |   |   |   |             |                         |                              |   |
| est for overall effect: z =   | = 0.73 ( <i>P</i> = .47)   |  |  | DE E0/   |   |   |   |             | rs low Fio <sub>2</sub> | Favors high Fio <sub>2</sub> |   |
| est for overall effect: z =<br>est for subgroup differe   | = 0.73 ( <i>P</i> = .47)   |  |  | 35.5%  |   |   |   |             | rs low Fio <sub>2</sub> | Favors high Fio <sub>2</sub> |   |
|   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88   | , df = 1 ( <i>P</i> :  | = .009); I <sup>2</sup> = 8  |  |   | 55  |   |             | 2                       | L.                           |   |
| est for subgroup differe  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Lov</b>  | , df = 1 ( <i>P</i> :<br><b>/ Fio</b> ₂  | = .009); l <sup>2</sup> = 8<br>Preterm, Hig  | gh Fio <sub>2</sub>  | Woight  | RR<br>M-H RF 95% CI   |   |             | RF                      | र                            |   |
| est for subgroup differe  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br><b>Preterm, Lov</b><br><b>Events</b>  | , df = 1 ( <i>P</i> =<br>/ Fio <sub>2</sub><br>Total   | = .009); I <sup>2</sup> = 8  |  | Weight  | RR<br>M-H, RE, 95% CI   |   |             | 2                       | र                            |   |
| est for subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te   | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br>Preterm, Lov<br>Events<br>erm, RCT, blinc   | , df = 1 ( <i>P</i> :<br>/ Fio <sub>2</sub><br><u>Total</u><br>led   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events  | gh Fio₂<br>Total   |   | M-H, RE, 95% CI   |   |             | RF                      | र                            |   |
| est for subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br><b>Preterm, Lov</b><br>Events<br>erm, RCT, blinc<br>1   | , df = 1 ( <i>P</i> =<br>/ Fio <sub>2</sub><br><u>Total</u><br>led<br>34   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2   | gh Fio <sub>2</sub><br>Total<br>34   | 4.2%  | <b>M-H, RE, 95% CI</b><br>0.50 (0.05 to 5   | 5.26)   |             | RF                      | र                            |   |
| est for subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>Rabi 2011<br>Aguar 2013  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br>Preterm, Lov<br>Events<br>erm, RCT, blinc<br>1<br>4   | , df = 1 ( <i>P</i> =<br>/ Fio <sub>2</sub><br>Total<br>led<br>34<br>34  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2<br>7  | gh Fio₂<br>Total<br>34<br>26   | 4.2%<br>5 15.2%   | <b>M-H, RE, 95% CI</b><br>0.50 (0.05 to 5<br>0.44 (0.14 to 2  | 5.26)   |             | RF                      | र                            |   |
| est for subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>guar 2013<br>took 2014  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br><b>Preterm, Lov</b><br>Events<br>erm, RCT, blinc<br>1   | , df = 1 ( <i>P</i> =<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br>led<br>34<br>34<br>99  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94   | 4.2%<br>5 15.2%<br>18.7%  | M-H, RE, 95% CI<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7  | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| est for subgroup differe<br><b>:tudy or Subgroup</b><br><b>:.3.1 Mortality short-te</b><br>Rabi 2011<br>Quar 2013<br>Rook 2014  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br>Preterm, Lov<br>Events<br>erm, RCT, blinc<br>1<br>4   | , df = 1 ( <i>P</i> =<br>/ Fio <sub>2</sub><br>Total<br>led<br>34<br>34  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2<br>7  | gh Fio₂<br>Total<br>34<br>26   | 4.2%<br>5 15.2%<br>18.7%  | <b>M-H, RE, 95% CI</b><br>0.50 (0.05 to 5<br>0.44 (0.14 to 2  | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| est for subgroup differe<br>.3.1 Mortality short-te<br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br>Jubtotal (95% CI)<br>Total events  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br><b>Preterm, Lov</b><br><u>Events</u><br>erm, RCT, blinc<br>1<br>4<br>6  | , df = 1 ( <i>P</i> =<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br>led<br>34<br>34<br>99<br>167   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br><u>Events</u><br>2<br>7<br>10<br>19   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94   | 4.2%<br>5 15.2%<br>18.7%  | M-H, RE, 95% CI<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7  | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| est for subgroup differe<br>.3.1 Mortality short-te<br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br>Jubtotal (95% CI)<br>Total events  | = 0.73 ( <i>P</i> = .47)<br>nces: χ <sup>2</sup> = 6.88<br><b>Preterm, Lov</b><br><u>Events</u><br>erm, RCT, blinc<br>1<br>4<br>6  | , df = 1 ( <i>P</i> =<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br>led<br>34<br>34<br>99<br>167   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br><u>Events</u><br>2<br>7<br>10<br>19   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94   | 4.2%<br>5 15.2%<br>18.7%  | M-H, RE, 95% CI<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7  | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| est for subgroup differe<br><b>itudy or Subgroup</b><br><b>J.3.1 Mortality short-te</b><br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br><b>Subtotal (95% CI)</b><br>Total events<br>Heterogeneity. $\tau^2 = 0.000$  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Lov<br>Events<br>arm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =   | , df = 1 ( <i>P</i> =<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br>led<br>34<br>34<br>99<br>167<br>: 2 ( <i>P</i> = .94   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br><u>Events</u><br>2<br>7<br>10<br>19   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94   | 4.2%<br>5 15.2%<br>18.7%  | M-H, RE, 95% CI<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7  | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>guar 2013<br>Rook 2014<br>ubtotal (95% Cl)<br>total events<br>Heterogeneity. $\tau^2 = 0.00$<br>test for overall effect: z  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Lov<br>Events<br>erm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>erm, RCT, unbl   | , df = 1 ( <i>P</i> :<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br><b>led</b><br>34<br>34<br>99<br>167<br>: 2 ( <i>P</i> = .94)<br>inded  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2<br>7<br>10<br>19<br>↔; I <sup>2</sup> = 0%                        | gh Fio₂<br>Total<br>34<br>26<br>94<br>154  | 4.2%<br>5 15.2%<br>4 18.7%<br>5 38.1%   | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7<br>0.51 (0.25 to 1   | 5.26)<br>1.34)<br>1.51)   |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>abi 2011<br>guar 2013<br>took 2014<br>ubtotal (95% CI)<br>otal events<br>leterogeneity. $\tau^2 = 0.00$<br>est for overall effect: z<br>.3.2 Mortality short-te  | $\begin{array}{l} \textbf{p} = 0.73 \ (P = .47)\\ \textbf{nces: } \chi^2 = 6.88\\ \textbf{Preterm, Lov}\\ \textbf{Events}\\ \textbf{rm, RCT, blinc}\\ 1\\ 4\\ 6\\ 11\\ 0; \ \chi^2 = 0.12, \ df = \\ = 1.90 \ (P = .06) \end{array}$   | , df = 1 ( <i>P</i><br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br><b>ied</b><br>34<br>39<br>167<br>52 ( <i>P</i> = .94   | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br><u>Events</u><br>2<br>7<br>10<br>19   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94   | 4.2%<br>5 15.2%<br>4 18.7%<br>5 38.1%   | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7<br>0.51 (0.25 to 1   | 5.26)<br>1.34)<br>1.51)<br>.02)   |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>.guar 2013<br>took 2014<br>ubtotal (95% Cl)<br>otal events<br>teterogeneity. $\tau^2 = 0.00$<br>est for overall effect: z<br>.3.2 Mortality short-te<br>larling 2005  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Lov<br>Events<br>erm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>erm, RCT, unbl   | , df = 1 ( <i>P</i> :<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br><b>led</b><br>34<br>34<br>99<br>167<br>: 2 ( <i>P</i> = .94)<br>inded  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2<br>7<br>10<br>19<br>↔; I <sup>2</sup> = 0%                        | gh Fio₂<br>Total<br>34<br>26<br>94<br>154  | 4.2%<br>5 15.2%<br>18.7%<br>38.1%   | M-H, RE, 95% CI<br>0.50 (0.05 to 5<br>0.44 (0.14 to 7<br>0.57 (0.22 to 7<br>0.51 (0.25 to 1<br>0.80 (0.24 to 2  | 5.26)<br>1.34)<br>1.51)<br>.02)<br>2.65)  |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>Rabi 2011<br>Subotal (95% CI)<br>total events<br>Heterogeneity. $\tau^2 = 0.000$<br>test for overall effect: z<br>.3.2 Mortality short-te<br>larling 2005<br>undstrom 1995   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Low</b><br><b>Events</b><br>erm, <b>RCT, blinc</b><br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>erm, <b>RCT, unbl</b><br>4  | , df = 1 ( <i>P</i> =<br><b>/ Fio</b> <sub>2</sub><br><b>Total</b><br><b>ied</b><br>34<br>34<br>99<br>167<br>5 2 ( <i>P</i> = .94<br>)<br><b>inded</b><br>26   | = .009); $ ^2 = 8$<br>Preterm, Hig<br>Events<br>2<br>7<br>10<br>19<br>2); $ ^2 = 0\%$<br>5                                   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154  | 4.2%<br>5 15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%  | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.80 (0.24 to 2<br>0.34 (0.07 to 2  | 5.26)<br>1.34)<br>1.51)<br>.02)<br>2.65)<br>1.58)   |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>.guar 2013<br>took 2014<br>ubtotal (95% CI)<br>otal events<br>teterogeneity. $\tau^2 = 0.00$<br>est for overall effect: z<br>.3.2 Mortality short-te<br>arling 2005<br>undstrom 1995<br>Vang 2008   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>arm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>erm, RCT, unbl<br>4<br>2<br>1  | , df = 1 ( <i>P</i> :<br><b>Total</b><br><b>ied</b><br>34<br>34<br>99<br>167<br>: 2 ( <i>P</i> = .94<br>)<br><b>inded</b><br>26<br>34<br>18  | = .009); I <sup>2</sup> = 8<br>Preterm, Hig<br>Events<br>2<br>7<br>10<br>19<br>(); I <sup>2</sup> = 0%<br>5<br>6<br>1        | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23                               | 4.2%<br>15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%<br>3.3%                                    | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.80 (0.24 to 2<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15  | 5.26)<br>1.34)<br>1.51)<br>.02)<br>2.65)<br>1.58)<br>9.06)  |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>a.1 Mortality short-te<br>abi 2011<br>aguar 2013<br>took 2014<br>ubtotal (95% CI)<br>otal events<br>deterogeneity. $\tau^2 = 0.00$<br>est for overall effect: z<br>a.2 Mortality short-te<br>larling 2005<br>undstrom 1995<br>Vang 2008<br>Yang 2008<br>Yang 2009   | $\begin{array}{c} = 0.73 \ (P = .47) \\ \text{nces: } \chi^2 = 6.88 \\ \hline \textbf{Preterm, Lov} \\ \hline \textbf{Events} \\ \text{erm, RCT, blinc} \\ 1 \\ 4 \\ 6 \\ 11 \\ 0; \ \chi^2 = 0.12, \ df = \\ 1.90 \ (P = .06) \\ \hline \textbf{erm, RCT, unbl} \\ 4 \\ 2 \\ 1 \\ 4 \\ 4 \end{array}$ | df = 1 (P) <b>Total Total 34 34 99 167 5</b> 2 (P = .94) <b>inded 26 34 18 37</b>  | $= .009);  ^{2} = 8$ Preterm, Hig<br>Events 2 7 10 19 4);  ^{2} = 0% 5 6 1 3   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>26<br>35<br>23<br>23<br>41                          | 4.2%<br>5 15.2%<br>4 18.7%<br>5 38.1%<br>5 13.7%<br>5 9.2%<br>5 3.3%<br>10.3%               | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.80 (0.24 to 2<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6   | 5.26)<br>.34)<br>.51)<br>.02)<br>2.65)<br>.58)<br>3.06)<br>3.17)  |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>guar 2013<br>took 2014<br>ubtotal (95% Cl)<br>otal events<br>Heterogeneity. $\tau^2 = 0.00$<br>cest for overall effect: z<br>.3.2 Mortality short-te<br>larling 2005<br>undstrom 1995<br>Vang 2008<br>(ento 2009<br>urmanian 2012   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Lov</b><br><b>Events</b><br><b>prm, RCT, blinc</b><br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br><b>prm, RCT, unbl</b><br>4<br>2<br>1<br>4<br>0  | df = 1 (P) <b>Total rotal rotal</b>  | = .009); $ ^2 = 8$<br><b>Preterm, Hig</b><br><b>Events</b><br>2<br>7<br>10<br>19<br>(); $ ^2 = 0\%$<br>5<br>6<br>1<br>3<br>0 | <b>gh Fio</b> <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>26<br>35<br>23<br>41<br>16                   | 4.2%<br>5 15.2%<br>4 18.7%<br>38.1%<br>5 13.7%<br>9.2%<br>6 3.3%<br>10.3%                   | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.80 (0.24 to 2<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim  | 5.26)<br>1.34)<br>1.51)<br>02)<br>2.65)<br>1.58)<br>9.06)<br>3.17)<br>able                                      |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>guar 2013<br>took 2014<br>subtotal (95% CI)<br>total events<br>teterogeneity. $\tau^2 = 0.00$<br>cest for overall effect: z<br>.3.2 Mortality short-te<br>larling 2005<br>undstrom 1995<br>Vang 2008<br>'ento 2009<br>irmanian 2012<br>capadia 2013   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Lov</b><br><b>Events</b><br><b>erm, RCT, blinc</b><br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br><b>erm, RCT, unbl</b><br>4<br>2<br>1<br>4<br>0<br>2   | df = 1 (P) <b>Total red 34 34 99 167 5</b> 2 (P = .94) <b>inded 26 34 18 377 16 44</b>   | = .009); $ ^2 = 8$<br>Preterm, Hig<br>Events<br>2<br>7<br>10<br>19<br>4); $ ^2 = 0\%$<br>5<br>6<br>1<br>3<br>0<br>3          | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23<br>41<br>16<br>44             | 4.2%<br>5 15.2%<br>4 18.7%<br>5 38.1%<br>9.2%<br>6 3.3%<br>10.3%<br>7.3%                    | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2  | 5.26)<br>1.34)<br>1.51)<br>0.02)<br>2.65)<br>1.58)<br>3.06)<br>3.17)<br>able<br>3.80)                           |             | RF                      | र                            |   |
| tudy or Subgroup differe<br>tudy or Subgroup<br>.3.1 Mortality short-te<br>tabi 2011<br>.guar 2013<br>took 2014<br>ubtotal (95% CI)<br>otal events<br>teterogeneity. $\tau^2 = 0.00$<br>test for overall effect: z<br>.3.2 Mortality short-te<br>larling 2005<br>undstrom 1995<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2009<br>.rmanian 2012<br>apadia 2013<br>vei 2017  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Lov</b><br><b>Events</b><br><b>prm, RCT, blinc</b><br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br><b>prm, RCT, unbl</b><br>4<br>2<br>1<br>4<br>0  | df = 1 ( $P$ :<br><b>rotal</b><br><b>rotal</b><br><b>rotal</b><br><b>rotal</b><br><b>rotal</b><br>34<br>34<br>99<br>167<br><b>c</b> 2 ( $P$ = .94<br>)<br><b>inded</b><br>26<br>34<br>18<br>37<br>16<br>44<br>144  | = .009); $ ^2 = 8$<br><b>Preterm, Hig</b><br><b>Events</b><br>2<br>7<br>10<br>19<br>(); $ ^2 = 0\%$<br>5<br>6<br>1<br>3<br>0 | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>41<br>34 | 4.2%<br>5.15.2%<br>4.18.7%<br>38.1%<br>5.13.7%<br>9.2%<br>5.3.3%<br>10.3%<br>7.3%<br>18.1%  | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7                     | 5.26)<br>34)<br>51)<br>02)<br>2.65)<br>1.58)<br>9.06)<br>5.17)<br>able<br>8.80)<br>7.52)                        |             | RF                      | र                            |   |
| est for subgroup differe<br><b>Study or Subgroup</b><br><b>I.3.1 Mortality short-te</b><br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br><b>Subtotal (95% CI)</b><br>Total events<br>Heterogeneity. $r^2 = 0.00$<br>Test for overall effect: z<br><b>I.3.2 Mortality short-te</b><br>Harling 2005<br>Lundstrom 1995<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2012<br>Capadia 2013<br>Dei 2017<br>Subtotal (95% CI)   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br><b>Preterm, Low</b><br><b>Events</b><br>erm, <b>RCT, blinc</b><br>1<br>4<br>6<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>erm, <b>RCT, unbl</b><br>4<br>2<br>1<br>4<br>0<br>2<br>1<br>4   | df = 1 (P) <b>Total red 34 34 99 167 5</b> 2 (P = .94) <b>inded 26 34 18 377 16 44</b>   | $= .009);  ^{2} = 8$ Preterm, Hig<br>Events 2 7 10 19 2);  ^{2} = 0% 5 6 1 3 0 3 5   | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23<br>41<br>16<br>44             | 4.2%<br>5.15.2%<br>4.18.7%<br>38.1%<br>5.13.7%<br>9.2%<br>5.3.3%<br>10.3%<br>7.3%<br>18.1%  | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7                     | 5.26)<br>34)<br>51)<br>02)<br>2.65)<br>1.58)<br>9.06)<br>5.17)<br>able<br>8.80)<br>7.52)                        |             | RF                      | र                            |   |
| est for subgroup differe<br><b>itudy or Subgroup</b><br><b>i.3.1 Mortality short-te</b><br>Rabi 2011<br>Sook 2014<br><b>iubtotal (95% CI)</b><br>otal events<br>Heterogeneity. $\tau^2 = 0.00^{\circ}$<br>rest for overall effect: z<br><b>i.3.2 Mortality short-te</b><br>Harling 2005<br>undstrom 1995<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2008<br>Vang 2017<br><b>iubtotal (95% CI)</b><br>otal events<br>Heterogeneity. $\tau^2 = 0.14$  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>rm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>prm, RCT, unbl<br>4<br>2<br>1<br>4<br>0<br>2<br>14<br>; $\chi^2$ = 6.28, df =   | $df = 1 (P = \frac{1}{2})$ $rotal$ | $   = .009  ;   ^{2} = 8$ Preterm, Hig<br>Events 2 7 10 19 (.);   ^{2} = 0% 5 6 1 3 0 3 5 23                                 | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>41<br>34 | 4.2%<br>5.15.2%<br>4.18.7%<br>38.1%<br>5.13.7%<br>9.2%<br>5.3.3%<br>10.3%<br>7.3%<br>18.1%  | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7                     | 5.26)<br>34)<br>51)<br>02)<br>2.65)<br>1.58)<br>9.06)<br>5.17)<br>able<br>8.80)<br>7.52)                        |             | RF                      | र                            |   |
|   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>rm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>prm, RCT, unbl<br>4<br>2<br>1<br>4<br>0<br>2<br>14<br>; $\chi^2$ = 6.28, df =   | $df = 1 (P = \frac{1}{2})$ $rotal$ | $   = .009  ;   ^{2} = 8$ Preterm, Hig<br>Events 2 7 10 19 (.);   ^{2} = 0% 5 6 1 3 0 3 5 23                                 | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>41<br>34 | 4.2%<br>15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%<br>3.3%<br>10.3%<br>7.3%<br>18.1%<br>61.9% | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7                     | 5.26)<br>1.34)<br>1.51)<br>0.02)<br>2.65)<br>1.58)<br>3.06)<br>3.17)<br>able<br>3.80)<br>7.52)<br>2.15)         |             | RF                      | र                            |   |
| est for subgroup differe<br><b>Study or Subgroup</b><br><b>I.3.1 Mortality short-te</b><br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br><b>Subtotal (95% CI)</b><br>Total events<br>Heterogeneity. $\tau^2 = 0.00$<br>Fest for overall effect: z<br><b>I.3.2 Mortality short-te</b><br>Harling 2005<br>.undstrom 1995<br>Wang 2008<br>/ento 2009<br>Armanian 2012<br>Kapadia 2013<br>Dei 2017<br><b>Subtotal (95% CI)</b><br>Total events<br>Heterogeneity. $\tau^2 = 0.14$<br>Fest for overall effect: z  | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>rm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>prm, RCT, unbl<br>4<br>2<br>1<br>4<br>0<br>2<br>14<br>; $\chi^2$ = 6.28, df =   | $df = 1 (P = \frac{1}{2})$ $rotal$ | $   = .009  ;   ^{2} = 8$ Preterm, Hig<br>Events 2 7 10 19 (.);   ^{2} = 0% 5 6 1 3 0 3 5 23                                 | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>143<br>328      | 4.2%<br>15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%<br>3.3%<br>10.3%<br>7.3%<br>18.1%<br>61.9% | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7<br>1.12 (.0.58 to 2 | 5.26)<br>1.34)<br>1.51)<br>0.02)<br>2.65)<br>1.58)<br>3.06)<br>3.17)<br>able<br>3.80)<br>7.52)<br>2.15)         |             | RF                      | र                            |   |
| est for subgroup differe<br><b>itudy or Subgroup</b><br><b>i.3.1 Mortality short-te</b><br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br><b>itubtotal (95% CI)</b><br>iotal events<br>Heterogeneity. $\tau^2 = 0.00$<br>fest for overall effect: $z$<br><b>i.3.2 Mortality short-te</b><br>Harling 2005<br>undstrom 1995<br>Vang 2008<br>Yang 2008<br>Yang 2008<br>Yang 2008<br>Yang 2008<br>Yang 2012<br>Lapadia 2013<br>Dei 2017<br>Subtotal (95% CI)<br>Total events<br>Heterogeneity. $\tau^2 = 0.14$<br>Test for overall effect: $z$<br>Total (95% CI)<br>Total events | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>prm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>prm, RCT, unbl<br>4<br>2<br>1<br>4<br>0<br>2<br>14<br>; $\chi^2$ = 6.28, df =<br>= 0.33 ( $P$ = .74<br>38                          | df = 1 (P = 1) $Total$ $Total$ $34$ $34$ $99$ $167$ $2 (P = .94)$ $167$ $26$ $34$ $18$ $37$ $16$ $44$ $144$ $319$ $5 (P = .28)$ $486$  |  | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>143<br>328      | 4.2%<br>15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%<br>3.3%<br>10.3%<br>7.3%<br>18.1%<br>61.9% | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7<br>1.12 (.0.58 to 2 | 5.26)<br>1.34)<br>1.51)<br>.02)<br>2.65)<br>1.58)<br>3.06)<br>3.17)<br>able<br>3.80)<br>7.52)<br>2.15)<br>1.37) | Favor       | RF                      | 3<br>95% CI                  |   |
| est for subgroup differe<br><b>(tudy or Subgroup</b><br><b>(.3.1 Mortality short-te</b><br>Rabi 2011<br>Aguar 2013<br>Rook 2014<br><b>Subtotal (95% CI)</b><br>Total events<br>Heterogeneity. $\tau^2 = 0.00$<br>Test for overall effect: z<br><b>(.3.2 Mortality short-te</b><br>Harling 2005<br>undstrom 1995<br>Vang 2008<br>Vento 2009<br>vrmanian 2012<br>Capadia 2013<br>Dei 2017<br>Subtotal (95% CI)<br>Total events<br>Heterogeneity. $\tau^2 = 0.14$<br>Test for overall effect: z<br><b>Total (95% CI)</b>   | = 0.73 ( $P$ = .47)<br>nces: $\chi^2$ = 6.88<br>Preterm, Low<br>Events<br>prm, RCT, blinc<br>1<br>4<br>6<br>11<br>0; $\chi^2$ = 0.12, df =<br>= 1.90 ( $P$ = .06<br>prm, RCT, unbl<br>4<br>2<br>1<br>4<br>0<br>2<br>14<br>; $\chi^2$ = 6.28, df =<br>= 0.33 ( $P$ = .74<br>; $\chi^2$ = 9.79, df =     | df = 1 (P = 1) (P =        |  | gh Fio <sub>2</sub><br>Total<br>34<br>26<br>94<br>154<br>26<br>35<br>23<br>41<br>16<br>44<br>143<br>328      | 4.2%<br>15.2%<br>18.7%<br>38.1%<br>13.7%<br>9.2%<br>3.3%<br>10.3%<br>7.3%<br>18.1%<br>61.9% | M-H, RE, 95% Cl<br>0.50 (0.05 to 5<br>0.44 (0.14 to 2<br>0.57 (0.22 to 2<br>0.51 (0.25 to 1<br>0.51 (0.25 to 1<br>0.34 (0.07 to 2<br>1.28 (0.09 to 15<br>1.48 (0.35 to 6<br>Not estim<br>0.67 (0.12 to 2<br>2.78 (1.03 to 7<br>1.12 (.0.58 to 2 | 5.26)<br>1.34)<br>1.51)<br>0.02)<br>2.65)<br>1.58)<br>3.06)<br>3.17)<br>able<br>3.80)<br>7.52)<br>2.15)         | Favor       | RF                      | र                            | 1 |

#### **FIGURE 2**

Summary of results: Preterm newborns receiving respiratory support when comparing low with high Fio<sub>2</sub>. A, STM demonstrating studies by RoB. B, STM sensitivity analysis revealing studies that are blinded and unblinded.

4 minutes of age,<sup>41</sup> and the others revealed no statistically significant difference.<sup>26–28,30</sup> A summary of the data found on HR response within the first 10 minutes is reported in Supplemental Table 15.

None of the additional secondary outcomes that were deemed

important markers of morbidity revealed statistically significant differences. Results are detailed in Tables 7 through 11.

#### **Subgroup Analyses**

The predetermined subgroup analyses by gestational age ( $\leq$ 32 and  $\leq$ 28 weeks) all revealed no statistically significant differences when comparing lower with higher  $F_{10_2}$ . The RRs are reported in Tables 8 and 9. Results from 2 observational studies involving 1225 preterm newborns  $\leq$ 28 weeks' gestation reveal an association with a statistically significant benefit of starting with lower oxygen compared with higher oxygen concentration

| Outcome             | Study Design | No. Studies | No. Participants | Effect Estimate, RR (95% CI) | l <sup>2</sup> , % | GRADE Confidence |
|---------------------|--------------|-------------|------------------|------------------------------|--------------------|------------------|
| STM                 | RCT          | 8           | 837              | 0.93 (0.55 to 1.55)          | 15                 | Very low         |
| Long-term mortality | RCT          | 3           | 491              | 1.05 (0.32 to 3.39)          | 79                 | Very low         |
| NDI long-term       | RCT          | 3           | 389              | 1.14 (0.78 to 1.67)          | 0                  | Very low         |

# С

| ,   | Preterm,             | Low Fio,             | Preterm, H                 | ligh Fio           |        | RR                        | RR                                    |
|---|----------------------|----------------------|----------------------------|--------------------|--------|---------------------------|---------------------------------------|
| Study or Subgroup                             | Events               | Total                | Events                     | Total              | Weight | M-H, RE, 95% CI Year      | M-H, RE, 95% CI                       |
| 5.1 Studies with low                          | or unclear           | RoB                  |                            |                    |        |                           |                                       |
| Vang 2008                                     | 1                    | 8                    | 1                          | 12                 | 6.5%   | 1.50 (0.11 to 20.68) 2008 | · · · · · · · · · · · · · · · · · · · |
| /ento 2009                                    | 4                    | 37                   | 3                          | 41                 | 12.7%  | 1.48 (0.35 to 6.17) 2009  |                                       |
| Rabi 2011                                     | 0                    | 11                   | 1                          | 15                 | 5.1%   | 0.44 (0.02 to 9.98) 2011  | • • • •                               |
| apadia 2013                                   | 1                    | 15                   | 2                          | 15                 | 7.8%   | 0.50 (0.05 to 4.94) 2013  | · · · · · · · · · · · · · · · · · · · |
| Rook 2014                                     | 6                    | 53                   | 10                         | 42                 | 16.4%  | 0.48(0.19 to 1.20) 2014   |                                       |
| Aguar 2013                                    | 4                    | 34                   | 7                          | 26                 | 15.0%  | 0.44(0.14 to 1.34) 2014   |                                       |
| Subtotal (95% CI)                             |                      | 158                  |                            | 151                | 63.5%  | 0.60 (0.33 to 1.07)       | -                                     |
| otal events                                   | 16                   |                      | 24                         |                    |        |                           |                                       |
| leterogeneity. $\tau^2 = 0.0$                 | 0; $\chi^2 = 2.61$ , | df = 5 (P            | = .76); I <sup>2</sup> = 0 | 1%                 |        |                           |                                       |
| est for overall effect: z                     | = 1.72 ( <i>P</i> =  | .09)                 |                            |                    |        |                           |                                       |
| I.5.2 Study with high                         | RoB                  |                      |                            |                    |        |                           |                                       |
| Dei 2017                                      | 14                   | 74                   | 5                          | 84                 | 16.1%  | 3.18 (1.20 to 8.40) 2017  | · · · · · · · · · · · · · · · · · · · |
| ubtotal (95% CI)                              |                      | 74                   |                            | 84                 | 16.1%  | 3.18 (1.20 to 8.40)       |                                       |
| otal events                                   | 14                   |                      | 5                          |                    |        |                           |                                       |
| leterogeneity. Not app                        | olicable             |                      |                            |                    |        |                           |                                       |
| Test for overall effect:                      | z = 2.33 (P =        | = .02)               |                            |                    |        |                           |                                       |
| .5.3 Hypothetical larg                        | ge RCT               |                      |                            |                    |        |                           |                                       |
| hypothetical 2020                             | 189                  | 1000                 | 60                         | 1000               | 20.4%  | 3.15 (2.39 to 4.15) 2020  |                                       |
| Subtotal (95% CI)                             |                      | 1000                 |                            | 1000               | 20.4%  | 3.15 (2.39 to 4.15)       | •                                     |
| otal events                                   | 189                  |                      | 60                         |                    |        |                           |                                       |
| leterogeneity. Not app                        | olicable             |                      |                            |                    |        |                           |                                       |
| est for overall effect:                       |                      | < .00001)            |                            |                    |        |                           |                                       |
| otal (95% CI)                                 |                      | 1232                 |                            | 1235               | 100.0% | 1.17 (0.52 to 2.62)       |                                       |
| Total events                                  | 219                  |                      | 89                         |                    |        | . ,                       |                                       |
| leterogeneity. $\tau^2 = 0.8$                 |                      | 7, df = 7 ( <i>l</i> | ⊃ = .0002): l²             | <sup>2</sup> = 75% |        |                           |                                       |
| $i \in U \cup U \in U \in U$ , $U = U \cup U$ |                      |                      | /, .                       |                    |        |                           | 0.05 0.2 1 5 2                        |
| est for overall effect:                       | z = 0.38 (P)         | = 71)                |                            |                    |        |                           | Favors low Fio, Favors high Fio,      |

| П                              |                         |                      |                           |                      |                        |   |  |
|--------------------------------|-------------------------|----------------------|---------------------------|----------------------|------------------------|---|--|
| D                              | Preterm, l              | _ow Fio <sub>2</sub> | Preterm, H                | igh Fio <sub>2</sub> |                        | RR  | RR   |
| Study or Subgroup              | Events                  | Total                | Events                    | Total                | Weight                 | M-H, RE, 95% CI Year                            | M-H, RE, 95% CI  |
| 8.3.1 Mortality short-te       | erm, RCT                |                      |                           |                      |                        |   |  |
| Aguar 2013                     | 4                       | 34                   | 7                         | 26                   | 43.1%                  | 0.44 (0.14 to 134) 2014                         |  |
| Rook 2014<br>Subtotal (95% CI) | 6                       | 99<br><b>133</b>     | 10                        | 94<br><b>120</b>     | 56.9%<br><b>100.0%</b> | 0.57 (0.22 to 1.51) 2014<br>0.51 (0.24 to 1.06) |  |
| Total events                   | 10                      |                      | 17                        |                      |                        |   |  |
| Heterogeneity. $\tau^2 = 0.00$ | 0; χ² = 0.12, d         | If = 1 (P =          | .73); I <sup>2</sup> = 0% |                      |                        |   |  |
| Test for overall effect: z     | r = 1.81 ( <i>P</i> = . | 07)                  |                           |                      |                        |   |  |
|                                |                         |                      |                           |                      |                        |   |  |
|                                |                         |                      |                           |                      |                        |   | 0.05 0.2 1 5 20  |
|                                |                         |                      |                           |                      |                        |   | Favors low Fio <sub>2</sub> Favors high Fio <sub>2</sub> |

#### **FIGURE 3**

Summary of results: Preterm newborns receiving respiratory support when comparing low with high Fio<sub>2</sub> (continued). C, STM exploratory analysis, including a hypothetical large study. D, STM subgroup analysis Fio<sub>2</sub> 0.3 compared with Fio<sub>2</sub> 0.60 to 0.65. df, degrees of freedom; MH, Mantel-Haenszel.

with respect to long-term mortality (RR = 0.77 [95% CI 0.59 to 0.99];  $I^2 = 6\%$ ).<sup>35,36</sup>

Exploratory analysis was conducted to assess whether an additional large RCT involving 2000 patients ≤28 weeks' gestation (all studies combined have <500 total patients in this age subgroup) with STM results similar to those in the Tor2rpido study would change the point estimate and CI to favor high  $Fio_2$  (Fig 3C). If such a sufficiently large RCT were added, the random effectsmeta-analysis result would remain nonsignificant (RR = 1.17 [95% CI: 0.52 to 2.62];  $I^2 = 75\%$ ).

The predetermined subgroup analyses by F10<sub>2</sub> comparisons are

reported in Table 10. Researchers in 2 RCTs with 253 preterm newborns ( $\leq$ 32 weeks' gestation) compared initial F10<sub>2</sub> 0.30 with F10<sub>2</sub> 0.60 to 0.65. The pooled estimate for STM reveals no statistically significant difference (RR = 0.51 [95% CI 0.24 to 1.06]; I<sup>2</sup> = 0%; Fig 3D).<sup>32,37</sup> The other outcomes and subgroups by

| Outcome                     | Study Design | No. Studies | No. Participants | Effect Estimate, RR (95% CI) | l <sup>2</sup> , % | GRADE Confidence |
|-----------------------------|--------------|-------------|------------------|------------------------------|--------------------|------------------|
| STM                         | RCT          | 7           | 467              | 0.92 (0.43 to 1.94)          | 45                 | Very low         |
| Long-term mortality         | RCT          | 1           | 86               | 2.11 (0.86 to 5.19)          | N/A                | Very low         |
| NDI long-term               | RCT          | 1           | 69               | 1.08 (0.58 to 2.03)          | N/A                | Very low         |
| ROP                         | RCT          | 6           | 441              | 0.75 (0.43 to 1.33)          | 0                  | Very low         |
| NEC                         | RCT          | 6           | 441              | 1.62 (0.66 to 3.99)          | 0                  | Very low         |
| BPD                         | RCT          | 7           | 467              | 0.90 (0.64 to 1.28)          | 31                 | Very low         |
| Major IVH (grade III or IV) | RCT          | 6           | 441              | 0.84 (0.50 to 1.40)          | 12                 | Very low         |

N/A, not available.

#### **TABLE 10** Summary of Results of Fig. Subgroup Comparisons

| Outcomes  | Study Design | No. Studies | No. Participants | Effect Estimate, RR (95% CI) | l <sup>2</sup> , % | GRADE Confidence |
|---|--------------|-------------|------------------|------------------------------|--------------------|------------------|
| Subgroup Fio <sub>2</sub> 0.21 compared with 1.0 only |              |             |                  |                              |                    |                  |
| STM   | RCT          | 4           | 484              | 1.58 (0.70 to 3.55)          | 4                  | Very low         |
| Long-term mortality                                   | RCT          | 3           | 491              | 1.05 (0.32 to 3.39)          | 79                 | Very low         |
| NDI long-term   | RCT          | 3           | 389              | 1.14 (0.78 to 1.67)          | 0                  | Very low         |
| Subgroup Fio <sub>2</sub> 0.21–0.30                   |              |             |                  |                              |                    |                  |
| compared with 0.80–1.00 only                          |              |             |                  |                              |                    |                  |
| STM   | RCT          | 7           | 667              | 1.24 (0.61 to 2.4)           | 13                 | Very low         |
| Long-term mortality                                   | RCT          | 3           | 491              | 1.05 (0.32 to 3.39)          | 79                 | Very low         |
| NDI long-term   | RCT          | 3           | 389              | 1.146 (0.78 to 1.67)         | 0                  | Very low         |
| Subgroup Fio, 0.30 compared                           |              |             |                  |                              |                    |                  |
| with 0.60–0.65  |              |             |                  |                              |                    |                  |
| STM   | RCT          | 2           | 253              | 0.51 (0.24 to 1.06)          | 0                  | Moderate         |
| Long-term mortality                                   | RCT          | 2           | 253              | 0.58 (0.28 to 1.20)          | N/A                | Low              |
| NDI long-term   | RCT          | 2           | 174              | 0.96 (0.38 to 2.43)          | N/A                | Low              |

N/A, not available.

TABLE 11 Summary of Results for Subgroup Oxygen Saturation Targeting or No Targeting

| Outcomes   | Study Design | No. Studies | No. Participants | Effect Estimate RR (95% CI) | l², % | GRADE Confidence |
|--|--------------|-------------|------------------|-----------------------------|-------|------------------|
| Subgroup with no explicit<br>oxygen saturation targeting<br>STM<br>Subgroup with explicit oxygen<br>saturation targeting | RCT          | 2           | 121              | 0.58 (0.23 to 1.49)         | 0     | Very low         |
| STM  | RCT          | 8           | 847              | 0.92 (0.50 to 1.71)         | 28    | Very low         |
| Long-term mortality  | RCT          | 3           | 491              | 1.05 (0.32 to 3.39)         | 79    | Very low         |
| NDI long-term  | RCT          | 3           | 389              | 1.14 (0.78 to 1.67)         | 0     | Very low         |

N/A, not applicable.

 $F_{10_2}$  comparisons also reveal no statistically significant differences when comparing lower with higher  $F_{10_2}$ .

The last predetermined subgroup analysis was focused on those studies in which oxygen saturation targeting (by using pulse oximetry) was explicitly included as a cointervention (and those in which it was not). The pooled results reveal no statistically significant differences and are reported in Table 11.

#### **Certainty in the Point Estimates** (GRADE Analysis)

The GRADE summary for the primary outcomes is presented in Supplemental Table 16. RCTs (n = 10) are started at high certainty, and retrospective cohort studies (n = 4) are started at low certainty. Because of serious concerns with RoB, inconsistency, and imprecision, the certainty of the results was downgraded to very low for the majority of the outcomes. The expert opinion of the ILCOR NLS

Task Force was that it would be very unlikely that there were any additional unpublished studies given the intense clinical interest in this topic, the international reach and involvement of the committee, and the extensive search (including uncovering abstracts and conference proceedings). Therefore, the outcomes were not downgraded for publication bias. The rating of the importance of outcomes for the GRADE analysis were all "critical" or "important" and ranged from 6 to 9 on the 9-point scale.

#### TABLE 12 Comparison With Previous Meta-analyses

|                          | This study,<br>RR (95% CI); <i>n</i> | 0ei et al, <sup>42,a</sup><br>RR (95% CI); <i>n</i> | Saugstad et al, <sup>43,b</sup><br>RR (95% Cl); <i>n</i> | Brown et al, <sup>44,c</sup><br>RR (95% Cl); <i>n</i> |
|--------------------------|--------------------------------------|---|--|---|
| STM                      | 0.83 (0.50–1.37); 968                | 0.99 (0.52–1.91); 509                               | 0.62 (0.37–1.04); 677                                    | 0.65 (0.43–0.98); 484                                 |
| Long-term mortality      | 1.05 (0.32-3.39); 491                |   | _  | _   |
| NDI (1-3 y)              | 1.14 (0.78–1.67); 389                | _   | _  | _   |
| IVH (III—IV)             | 0.96 (0.61-1.51); 795                | _   | 0.90 (0.53-1.53); 677                                    | 1.50 (0.71–3.15); 240                                 |
| ROP (III—V)              | 0.73 (0.42–1.27); 806                | 0.78 (0.48-1.29); 419                               |  | 0.68 (0.24-1.96); 199                                 |
| NEC (II—III)             | 1.34 (0.63–2.84); 847                | 1.61 (0.77–3.36); 483                               | _  | 1.74 (0.42-7.20); 199                                 |
| BPD (moderate to severe) | 1.00 (0.71–1.40); 843                | 0.88 (0.68–1.14); 443                               | 1.11 (0.73–1.68); 677                                    | 0.86 (0.62–1.18); 223                                 |

RR <1 favors lower compared with higher Fio<sub>2</sub>. ---, not applicable.

a Data were as follows: Fio\_2 <0.3 compared with ≥0.6; age <29 wk; 6 articles and 2 abstracts, 4 were excluded; did not specify moderate to severe BPD; ROP ≥3; and NEC ≥2.

<sup>b</sup> Data were as follows: Fig.  $\leq$ 0.3 compared with  $\geq$ 0.6; age <32 wk; and IVH  $\geq$ 2.

<sup>c</sup> Data were as follows: Fio<sub>2</sub> ≤0.5 vs >0.5; most were age <32 wk; and no definition was given for BPD, ROP, NEC, or severe IVH.

#### **DISCUSSION**

In this systematic review and metaanalysis, we identified 10 RCTs involving 1007 preterm newborns (<35 weeks' gestation) and demonstrate no statistically significant improvement in STM when initiating respiratory support in newborns with low compared with high FIO<sub>2</sub>. There is also no statistically significant benefit in the other outcomes. However, the GRADE certainty of evidence for all outcomes assessed were very low because of issues with RoB, inconsistency, and imprecision.

Although concealed allocation was a common feature for most of the randomized studies, researchers in only 3 studies used oxygen saturation targeting and adequately masked the study gas from the delivery room personnel.<sup>29,32,37</sup> When considering all-cause STM, none of the studies revealed statistically significant effects of the initial oxygen concentration, but the 3 fully masked studies had similar point estimates, and each favored lower initial oxygen concentrations.

In contrast, the recently published To2rpido study was nonblinded.<sup>41</sup> Although it is the largest RCT reported to date, after 6.5 years of enrollment, the study had to be terminated with only 15% of planned enrollment (292 of 1976) completed. Only 4.6% (292 of 6291) of eligible subjects were enrolled secondary to clinician preference, lack of equipoise, and inability of the study

team to attend many births. Therefore, the study was determined to be at an overall high RoB. The study's primary outcome was death or disability at 2 years; however, when the study was terminated, investigators reported a statistically significant increased risk of death before hospital discharge (RR 3.9; 95% CI 1.1 to 13.4) among newborns <28 weeks' gestation who were randomly assigned to the room air group. This was not a prespecified outcome and thus should be interpreted with caution. Comparing STM from the To2rpido study with the other 6 studies in which outcomes for newborns ≤28 weeks' gestation were reported, To2rpido subjects had both the highest reported proportion of deaths in the low Fio<sub>2</sub> group (19%) and the lowest proportion of deaths in the high Fio<sub>2</sub> group (6%). Because of the small number of extremely preterm subjects, the increased risk of all deaths reported in the To2rpido study reflects a difference in mortality for only 6 subjects over the 6.5 years of study enrollment and may represent a type I ( $\alpha$ ) error. In sensitivity analysis, removing this study shifts the summary estimate of STM to favor lower oxygen (RR 0.63; 95% CI 0.38 to 1.03) with no heterogeneity ( $I^2 =$ 0%), whereas including it shifts the effect estimate toward the null effect line (RR 0.83; 98% CI 0.50 to 1.37) and increases heterogeneity ( $I^2 = 18\%$ ).

The findings in this meta-analysis are seemingly contradictory to the

evidence that high  $F_{10_2}$  can be toxic to newborns, especially preterm newborns. As has been recognized for decades, free radical formation from hyperoxia can cause injury to the newborn lungs, eyes, brain, and other organs.<sup>6</sup> Researchers in the original delivery room oxygen studies of term newborns examined only  $F_{10_2}$  0.21 compared with  $F_{10_2}$  1.0 and demonstrated evidence of a STM benefit of initial room air resuscitation. However, the more recent preterm studies do not reveal this same effect.

Contemporary practice involves oxygen saturation targeting with pulse oximetry and was included as a cointervention in the 8 most recent RCTs and all 4 observational studies.<sup>5,</sup> <sup>26–33,36,37</sup> Among RCTs in which researchers used oxygen saturation targeting, nearly all subjects who were randomly assigned to initiate resuscitation with room air required the administration of supplemental oxygen to meet desired targets.<sup>5,26,29,31</sup> With oxygen saturation targeting, control and intervention subjects were exposed to different inspired oxygen concentrations for the first 5 to 7 minutes of life,<sup>5,26,28,31,37</sup> which may have limited the effect of the intervention.

In Table 12, we compare this metaanalysis to key previously published analyses. The STM RRs for low compared with high  $F_{10_2}$  are different in the analyses published before the To2rpido study because that study had a negative point estimate for mortality. This shifted the subsequent point estimates and CIs to a nonsignificant finding of neither harm nor benefit.

In 2010, the ILCOR recommended initial room air for term neonatal resuscitation.<sup>45</sup> Although this was not intended to apply to preterm newborns, there were some publications in which researchers studied preterm subjects that had revealed no apparent harm from starting resuscitation with  $F_{10_2}$  <1.0, and some centers began changing to initial room air resuscitation in preterm newborns in addition to term newborns. Since then, researchers in several RCTs of oxygen administration to preterm newborns found recruitment difficult because clinicians lost equipoise in using F10, 1.0 for the initial resuscitation of preterm newborns.5,27

In 2015, the ILCOR NLS Task Force made the recommendation to begin the resuscitation of preterm newborns (<35 weeks' gestation) with a low oxygen concentration (Fio2 0.21-0.30) and recommended against the use of high supplementary oxygen concentrations (Fio<sub>2</sub> 0.65–1.0; strong recommendation, moderate quality evidence). This was a major change for many regions of the world that had a long-standing practice of starting with 100% oxygen for respiratory support in all preterm newborns who received respiratory support at birth. In making such a recommendation, high value was placed on not exposing preterm newborns to additional oxygen without proven benefit for critical or important outcomes.

In this analysis in 2018 (in collaboration with the ILCOR), we considered preterm newborns <35 weeks' gestation and defined low oxygen as  $Fio_2 0.21$  to 0.50 and high oxygen as  $Fio_2 0.51$  to 1.0 (with planned subgroup analyses based on specific  $Fio_2$  comparisons). Low  $Fio_2$  was considered to be the intervention and high  $Fio_2$  was the comparison. Thus, the relative risks are the inverse of the previous

ILCOR 2015 review. Additional studies and trials have become available since the 2015 CoSTR and included data regarding long-term NDI. However, even with the new information and 1 larger trial in which researchers reported an increased risk of mortality for low oxygen in a secondary analysis of newborns  $\leq$ 28 weeks' gestation, the outcomes remain similar to those in the previous review. Although the point estimates have shifted somewhat, and CIs have widened, there is no clear advantage in using either low or high Fio<sub>2</sub> for the outcomes considered, even the critical outcome of mortality. The ILCOR CoSTR associated with this analysis will be published separately in an ILCOR 2019 update.

The strengths of this systematic review and meta-analysis include a prespecified protocol; a broad search strategy, including additional unpublished data from authors; sensitivity analyses, the use of GRADE to determine certainty in effect estimate; a strong team of expert systematic reviewers coupled with international multidisciplinary experts in neonatology; and adherence to PRISMA reporting.

There are, however, several limitations. Firstly, 8 of the 12 RCT publications have an unclear RoB, and 1 RCT, the To2rpido study, has a high RoB.<sup>5,38</sup> The RoB as well as imprecision make the certainty of the point estimates low or very low. We also observed heterogeneity in several analyses, although this was primarily due to the To2rpido study. Variation in interventions and methods of defining outcomes (eg, NDI) across included studies may have contributed to heterogeneity. Lastly, the included studies enrolled patients from 1991 to 2014. During this time, clinical practice and guidelines have changed considerably. It is unclear if similar results would be found with current clinical practice.

#### CONCLUSIONS

In this systematic review and metaanalysis, comparison of initial low with high F102 for preterm newborns <35 weeks' gestation who receive respiratory support at birth demonstrates no consistent evidence to define the ideal initial F102. The data do reveal, however, that nearly all preterm newborns ≤32 weeks' gestation will require oxygen supplementation in the first 5 minutes after delivery to achieve commonly recommended oxygen saturation targets. Future researchers should focus on identifying the optimum initial F<sub>102</sub> together with the ideal target oxygen saturation. Adequately powered studies in which researchers report long-term neurodevelopmental outcomes are required.

#### ACKNOWLEDGMENTS

The authors would like to express their appreciation to the following for contributing valuable support to improve this review: Laurie J. Morrison (ILCOR Continuous Evidence Evaluation Working Group Liaison), and Carolyn Ziegler (St. Michael's Hospital Information Specialist). The authors would also like to highlight the following researchers who kindly contributed valuable information and data from their studies to improve this review: Jennifer Dawson, Vishal Kapadia, Ju Lee Oei, Yacov Rabi, and Maximo Vento.

Besides the authors Tetsuya Isayama, Charles Christoph Roehr, Myra H. Wyckoff, and Yacov Rabi, members of the International Liaison Committee on Resuscitation Neonatal Life Support Task Force include: Jonathan Wyllie, Jeffrey M. Perlman, Khalid Aziz, Ruth Guinsburg, Maria Fernanda de Almeida, Vishal Kapadia, Daniele Trevisanuto, Sithembiso Velaphi, Lindsay Mildenhall, Helen Liley, Shigeharu Hosono, Han-Suk Kim, and Edgardo Szyld.

| ABBREVIATIONS<br>BPD: bronchopulmonary dysplasia<br>CI: confidence interval<br>CINAHL: Cumulative Index to<br>Nursing and Allied Health<br>Literature<br>CoSTR: consensus on science with<br>treatment<br>recommendations<br>EBM: Evidence-Based Medicine<br>F10 <sub>2</sub> : fraction of inspired oxygen<br>GRADE: Grading of<br>Recommendations | Assessment, Development<br>and Evaluation<br>HR: heart rate<br>ILCOR: International Liaison<br>Committee on Resuscitation<br>IQR: interquartile range<br>IVH: intraventricular hemorrhage<br>NDI: neurodevelopmental<br>impairment<br>NEC: necrotizing enterocolitis<br>NLS: Neonatal Life Support<br>PRISMA: Preferred Reporting Items<br>for Systematic Reviews<br>and Meta-analyses | RCT: randomized controlled trial<br>RoB: risk of bias<br>ROBINS-I: Risk of Bias in<br>Nonrandomized Studies<br>of Interventions<br>ROP: retinopathy of prematurity<br>RR: risk ratio<br>STM: short-term mortality<br>To2rpido: Targeted Oxygen in the<br>Resuscitation of Preterm<br>Infants and Their<br>Developmental<br>Outcomes |
|---|--|---|
|---|--|---|

of Texas Southwestern Medical Center, Dallas, Texas; <sup>j</sup>Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; and <sup>k</sup>Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada

Dr Welsford prepared the protocol, screened studies, abstracted data, completed risk-of-bias and Grading of Recommendations Assessment, Development and Evaluation evaluations, completed the analysis, and prepared the first draft of the manuscript; Dr Nishiyama reviewed the protocol, screened studies, abstracted data, completed risk-of-bias and Grading of Recommendations Assessment, Development and Evaluation evaluations, reviewed the analysis, and prepared the first draft of the manuscript; Dr Nishiyama reviewed the analysis, and prepared the first draft of the manuscript; Dr Shortt reviewed the protocol, screened studies, abstracted data, prepared the tables, and was involved in writing and editing the manuscript; Drs Weiner and Roehr reviewed the protocol, completed risk-of-bias and Grading of Recommendations Assessment, Development and Evaluation evaluations, reviewed the analysis, and were involved in writing and editing the manuscript; Drs Isayama, Dawson, Wyckoff, and Rabi were involved in reviewing the protocol, reviewing the analysis, and writing and editing the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

This trial has been registered with the Prospective Register of Systematic Reviews (https://www.crd.york.ac.uk/prospero/) (identifier CRD42018084902).

DOI: https://doi.org/10.1542/peds.2018-1828

Accepted for publication Sep 11, 2018

Address correspondence to Michelle Welsford, BSc, MD, FRCPC, Division of Emergency Medicine, McMaster University, Centre for Paramedic Education and Research, Hamilton General Hospital, McMaster Clinic, 237 Barton St E., Room 253, Hamilton, ON L8L 2X2, Canada. E-mail: welsford@mcmaster.ca

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2019 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Funded by the American Heart Association on behalf of the International Liaison Committee on Resuscitation. The funder was involved in the International Liaison Committee on Resuscitation process but had no role in the systematic review study design, data collection and analysis, or preparation of the article.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

COMPANION PAPER: Companions to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2018-1825 and www.pediatrics.org/cgi/doi/ 10.1542/peds.2018-3365.

#### REFERENCES

- Morley PT, Lang E, Aickin R, et al. Part 2: evidence evaluation and management of conflicts of interest: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Circulation*. 2015;132(16, suppl 1):S40–S50
- Perlman JM, Wyllie J, Kattwinkel J, et al. Part 7: neonatal resuscitation: 2015 international consensus on

cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Circulation*. 2015;132(16, suppl 1):S204–S241

- Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2015;132(18, suppl 2):S543–S560
- Wyllie J, Bruinenberg J, Roehr CC, Rüdiger M, Trevisanuto D, Urlesberger B. European Resuscitation Council guidelines for resuscitation 2015: section 7. Resuscitation and support of transition of babies at birth. *Resuscitation*. 2015;95:249–263
- 5. Oei JL, Saugstad OD, Lui K, et al. Targeted oxygen in the resuscitation of preterm infants, a randomized clinical trial. *Pediatrics*. 2017;139(1): e20161452

- Vento M, Sastre J, Asensi MA, Viña J. Room-air resuscitation causes less damage to heart and kidney than 100% oxygen. *Am J Respir Crit Care Med.* 2005;172(11):1393–1398
- Weinberger B, Laskin DL, Heck DE, Laskin JD. Oxygen toxicity in premature infants. *Toxicol Appl Pharmacol.* 2002;181(1):60–67
- Hooper SB, Polglase GR, Roehr CC. Cardiopulmonary changes with aeration of the newborn lung. *Paediatr Respir Rev.* 2015;16(3): 147–150
- 9. World Health Organization. In: Howson C, Kinney M, Lawn J, eds. *Born Too Soon: The Global Action Report on Preterm Birth.* Geneva, Switzerland: WH0; 2012
- Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions.Version 5.1.0. London, United Kingdom: The Cochrane Collaboration; 2011. Available at: www.handbook.cochrane.org. Accessed May 27, 2018
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097
- Strand M, Simon W, Wyllie J, Wyckoff M, Weiner G. Consensus outcome rating for international neonatal resuscitation guidelines. In: *Pediatric Academic Societies Meeting*; May 5–8, 2018; Toronto, Canada
- Bayley N. Bayley Scales of Infant and Toddler Development. 3rd ed. San Antonio, TX: Harcourt Assessment; 2006
- Younge N, Goldstein RF, Bann CM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Survival and neurodevelopmental outcomes among periviable infants. N Engl J Med. 2017;376(7):617–628
- Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr*. 1978;92(4):529–534

- Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. *Pediatr Clin North Am*. 1986;33(1):179–201
- Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729
- Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary dysplasia: executive summary of a workshop. *J Pediatr*. 2018;197:300–308
- 19. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. *Arch Ophthalmol.* 2005;123(7):991–999
- Higgins JPT, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343(7829):d5928
- Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919
- 22. Schünemann HB, Guyatt G, Oxman A. *GRADE Handbook*.The GRADE Working Group; 2013. Available at: www. guidelinedevelopment.org/handbook. Accessed May 27, 2018
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–560
- Lundstrøm KE, Pryds O, Greisen
   G. Oxygen at birth and prolonged cerebral vasoconstriction in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1995;73(2):F81–F86
- 25. Harling AE, Beresford MW, Vince GS, Bates M, Yoxall CW. Does the use of 50% oxygen at birth in preterm infants reduce lung injury? *Arch Dis Child Fetal Neonatal Ed.* 2005;90(5):F401–F405
- Wang CL, Anderson C, Leone TA, Rich W, Govindaswami B, Finer NN. Resuscitation of preterm neonates by using room air or 100% oxygen. *Pediatrics.* 2008;121(6):1083–1089
- 27. Dawson JA, Kamlin COF, Wong C, et al. Oxygen saturation and heart rate

- during delivery room resuscitation of infants <30 weeks' gestation with air or 100% oxygen. Arch Dis Child Fetal Neonatal Ed. 2009;94(2):F87–F91
- Vento M, Moro M, Escrig R, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. *Pediatrics*. 2009;124(3). Available at: www.pediatrics.org/cgi/ content/full/124/3/e439
- Rabi Y, Singhal N, Nettel-Aguirre A. Room-air versus oxygen administration for resuscitation of preterm infants: the ROAR study. *Pediatrics*. 2011;128(2). Available at: www. pediatrics.org/cgi/content/full/128/2/ e374
- Armanian AM, Badiee Z. Resuscitation of preterm newborns with low concentration oxygen versus high concentration oxygen. J Res Pharm Pract. 2012;1(1):25–29
- 31. Kapadia VS, Chalak LF, Sparks JE, Allen JR, Savani RC, Wyckoff MH. Resuscitation of preterm neonates with limited versus high oxygen strategy. *Pediatrics*. 2013;132(6). Available at: www.pediatrics.org/cgi/ content/full/132/6/e1488
- 32. Aguar M, Brugada M, Escobar J, et al. Resuscitation of ELBW infants with initial Fi02 of 30% vs. 60%, a randomized, controlled, blinded study: the REOX trial. In: 2013 PAS Annual Meeting; May 4–7, 2013; Washington, DC
- Rabi Y, Lodha A, Soraisham A, Singhal N, Barrington K, Shah PS. Outcomes of preterm infants following the introduction of room air resuscitation. *Resuscitation*. 2015;96:252–259
- 34. Boronat N, Aguar M, Rook D, et al. Survival and neurodevelopmental outcomes of preterms resuscitated with different oxygen fractions. *Pediatrics*. 2016;138(6):e20161405
- Kapadia VS, Lal CV, Kakkilaya V, Heyne R, Savani RC, Wyckoff MH. Impact of the neonatal resuscitation programrecommended low oxygen strategy on outcomes of infants born preterm. *J Pediatr*. 2017;191:35–41
- Soraisham AS, Rabi Y, Shah PS, et al. Neurodevelopmental outcomes of preterm infants resuscitated with

different oxygen concentration at birth. *J Perinatol.* 2017;37(10):1141–1147

- Rook D, Schierbeek H, Vento M, et al. Resuscitation of preterm infants with different inspired oxygen fractions. *J Pediatr*. 2014;164(6):1322–1326.e3
- Thamrin V, Saugstad OD, Tarnow-Mordi W, et al. Preterm infant outcomes after randomization to initial resuscitation with Fi02 0.21 or 1.0. *J Pediatr*. 2018;201:55–61.e1
- 39. Escrig R, Arruza L, Izquierdo I, et al. Achievement of targeted saturation values in extremely low gestational age neonates resuscitated with low or high oxygen concentrations: a prospective, randomized trial. *Pediatrics*. 2008;121(5):875–881

- 40. Finer N. Study of room air versus 60% oxygen for resuscitation of premature infants (PRESOX). Available at: https://clinicaltrials.gov/ct2/show/ NCT01773746. Accessed May 27, 2018
- Oei JL, Finer NN, Saugstad OD, et al. Outcomes of oxygen saturation targeting during delivery room stabilisation of preterm infants. *Arch Dis Child Fetal Neonatal Ed.* 2018;103(5):F446–F454
- Oei JL, Vento M, Rabi Y, et al. Higher or lower oxygen for delivery room resuscitation of preterm infants below 28 completed weeks gestation: a metaanalysis. Arch Dis Child Fetal Neonatal Ed. 2017;102(1):F24–F30
- 43. Saugstad OD, Aune D, Aguar M, Kapadia V, Finer N, Vento M. Systematic review

and meta-analysis of optimal initial fraction of oxygen levels in the delivery room at  $\leq$ 32 weeks. *Acta Paediatr*. 2014;103(7):744–751

- Brown JV, Moe-Byrne T, Harden M, McGuire W. Lower versus higher oxygen concentration for delivery room stabilisation of preterm neonates: systematic review. *PLoS One.* 2012;7(12):e52033
- 45. Perlman JM, Wyllie J, Kattwinkel J, et al; Neonatal Resuscitation Chapter Collaborators. Part 11: neonatal resuscitation: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Circulation*. 2010;122(16, suppl 2): S516–S538

# Initial Oxygen Use for Preterm Newborn Resuscitation: A Systematic Review With Meta-analysis

Michelle Welsford, Chika Nishiyama, Colleen Shortt, Gary Weiner, Charles Christoph Roehr, Tetsuya Isayama, Jennifer Anne Dawson, Myra H. Wyckoff, Yacov Rabi and on behalf of the International Liaison Committee on Resuscitation Neonatal Life Support Task Force

*Pediatrics* 2019;143;

DOI: 10.1542/peds.2018-1828 originally published online December 21, 2018;

| Updated Information &<br>Services | including high resolution figures, can be found at:<br>http://pediatrics.aappublications.org/content/143/1/e20181828   |
|-----------------------------------|--|
| References                        | This article cites 38 articles, 19 of which you can access for free at: http://pediatrics.aappublications.org/content/143/1/e20181828#BIBL   |
| Subspecialty Collections          | This article, along with others on similar topics, appears in the following collection(s):<br>Evidence-Based Medicine<br>http://www.aappublications.org/cgi/collection/evidence-based_medic<br>ine_sub<br>Fetus/Newborn Infant<br>http://www.aappublications.org/cgi/collection/fetus:newborn_infant_<br>sub<br>Neonatology<br>http://www.aappublications.org/cgi/collection/neonatology_sub |
| Permissions & Licensing           | Information about reproducing this article in parts (figures, tables) or<br>in its entirety can be found online at:<br>http://www.aappublications.org/site/misc/Permissions.xhtml  |
| Reprints                          | Information about ordering reprints can be found online:<br>http://www.aappublications.org/site/misc/reprints.xhtml  |



# PEDIATRACES®

## Initial Oxygen Use for Preterm Newborn Resuscitation: A Systematic Review With Meta-analysis

Michelle Welsford, Chika Nishiyama, Colleen Shortt, Gary Weiner, Charles Christoph Roehr, Tetsuya Isayama, Jennifer Anne Dawson, Myra H. Wyckoff, Yacov Rabi and on behalf of the International Liaison Committee on Resuscitation Neonatal Life Support Task Force *Pediatrics* 2019;143; DOI: 10.1542/peds.2018-1828 originally published online December 21, 2018;

The online version of this article, along with updated information and services, is located on the World Wide Web at: http://pediatrics.aappublications.org/content/143/1/e20181828

Data Supplement at: http://pediatrics.aappublications.org/content/suppl/2018/12/17/peds.2018-1828.DCSupplemental

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2019 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

